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Introduction 
This section provides an introduction to the Report of Verified Case of Tuberculosis and an overview of 
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Tuberculosis (TB) is a nationally notifiable disease, in that reporting is mandated in all states. In 1953, a 
national surveillance system was established to collect information on new cases of active TB. Since 
1985, all states have been reporting TB cases to the Centers for Disease Control and Prevention (CDC)
using the Report of Verified Case of Tuberculosis (RVCT), the national TB surveillance form.  Data are 
collected by state and local TB programs and submitted electronically to CDC, Division of Tuberculosis 
Elimination (DTBE).  These data are used to monitor national TB trends, identify priority needs, and 
create the DTBE annual surveillance report, Reported Tuberculosis in the United States. 
 
To control and eventually eliminate TB, state and local TB control programs must be able to monitor 
trends in TB disease in high-risk populations, as well as identify new patterns of disease and possible 
outbreaks.  The last major revision of the RVCT was completed in 1993.  Since 2001, members of a 
DTBE-sponsored work group consisting of nearly 30 public health professionals from 15 TB control 
programs, DTBE, and the National TB Controllers Association (NTCA) have been working to revise the 
RVCT.  Modifications to the RVCT data collection now accommodate the changing epidemiology of TB 
in terms of risk factors, new drug treatments, and enhanced laboratory capacity for diagnostic tests.  
Note: A case of TB is defined as an episode of TB disease in a person meeting the laboratory or clinical 
criteria for TB as defined in Appendix A – Tuberculosis Case Definition for Public Health Surveillance. 
 
Tuberculosis Surveillance Data 
Some states may use a modified version of the RVCT or a data collection tool that is unique to their 
jurisdiction. These forms are used to collect the same data contained in the RVCT. However, just as the 
actual RVCT form is not sent to CDC, neither are these locally defined variables or additional data. CDC 
should never receive names of persons with TB. Names are retained by the state or local health 
department. Locally assigned numbers and characters are used for case identification and are included in 
Case Numbers (item 3) for use by CDC. See Case Numbers (item 3) for more information.
Impact of RVCT Data 
The revised RVCT will assist TB control programs in gathering accurate and useful data. The additions 
and changes made to the variables of the RVCT will enable programs to capture data that are more 
inclusive of a variety of risk factors.  These additional data will be essential to efficient and effective TB 
program management. The following table illustrates how the revised RVCT data can improve TB 
programs, and the consequences of having inaccurate or incomplete data.  
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Impact of Revised RVCT Data 
Benefits of RVCT Data  Consequences of Inaccurate, 
Incomplete, or Unknown RVCT Data 
• Increased ability to assess program 
performance, completeness of data 
collection, and accuracy of reporting  
 
• Improved data for program planning and 
policy development (e.g., personnel, 
resources, funding) 
• Facilitation of patient services (e.g., 
quality of care, continuity of care, 
sharing of accurate information with 
patient and health facilities) 
• Inaccurate follow-up of services to patients  
 
• Inadequate resources (e.g., funding, staff, 
facilities, drugs, and supplies) 
• Inaccurate evaluation and policy development 
 
• Misrepresentation of the public health burden 
of TB 
• Inability to measure TB program indicators that 
are based on surveillance data 
Quality Assurance
Assuring data completeness and quality is encouraged for all case reporting. Each reporting area should 
develop its own policy or procedure for reviewing and updating incomplete or incorrect data. These 
procedures should ensure that the data are collected and entered in the surveillance system accurately.  
Although health departments share TB surveillance data with CDC, the responsibility and authority for 
TB surveillance rests with the health department. States vary in the structure and organization of their 
surveillance systems, and often in the completeness or quality assurance of their case reporting. As with 
any reportable disease, the completeness of TB reporting reflects how actively health departments solicit 
case report information. Historically, disease surveillance systems have been categorized as passive or 
active.  
· Passive surveillance 
Health departments passively receive case reports from health care providers, depending on the 
health care providers to know and comply with reporting requirements. 
· Active surveillance 
Health departments actively contact and interact with health care facilities or individual providers 
to stimulate disease reporting, sometimes directly assuming the primary responsibility of 
reporting cases from large or high-volume institutions. 
CDC provides funding and technical assistance to health departments to actively stimulate TB case 
reporting, and has encouraged them to take an active rather than passive approach to TB surveillance. 
Health departments are encouraged to identify local or private health care facilities that serve TB patients. 
Health departments are also encouraged to use other data sources to identify TB cases, including death 
certificates and laboratory reports.  
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Overview of the RVCT Form 
The RVCT form is designed for the collection of information on cases of TB. The expanded RVCT was 
approved by the Office of Management and Budget (OMB) in 2008 to become effective January 2009. 
Note:  On the RVCT form and throughout this document, the term state is used to refer to the reporting  
jurisdiction (or count authority), though not all jurisdictions are states. 
 
Required and Recommended Uses of the RVCT 
The following table indicates the required and recommended uses of the RVCT. 
Required Use  
of the RVCT 
Additional Recommended Uses  
of the RVCT 
Possible Use of the RVCT for  
a Suspected Case of TB 
The RVCT must be 
completed for all 
verified cases of TB 
that are to be included 
in the reporting area’s 
annual morbidity 
count. 
CDC recommends the use of RVCT 
forms for the collection of data on the 
following: 
· Transfer TB cases (e.g., TB cases 
counted in another state or country) 
· TB cases that recur within 12 months 
after the completion of therapy 
Reporting areas may also use the 
RVCT forms for the collection of 
data on a suspected case of TB or 
on a patient with latent TB 
infection (LTBI). 
For the purposes of surveillance, a case of TB is defined on the basis of laboratory and/or clinical 
evidence of active disease due to M. tuberculosis complex. For more information on the case definition of 
M. tuberculosis complex, see Appendix A – Tuberculosis Case Definition for Public Health Surveillance.
Note:  The instructions contained in this document do not apply to suspected cases of TB or to                                                                                         
patients with latent TB infection (LTBI). 
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RVCT Form 
The expanded RVCT form comprises three data collection reports, which are printed in triplicate on 
carbonless paper: 
1.  Report of Verified Case of Tuberculosis: Complete this form for all patients with a verified case of 
TB. 
2.  Initial Drug Susceptibility Report (Follow-Up Report 1): Complete this form for all patients who 
had a culture that was positive for M. tuberculosis complex.  
3.  Case Completion Report (Follow-Up Report 2): Complete this form for all patients who were 
alive when TB was diagnosed.  
The two follow-up reports supplement the Report of Verified Case of Tuberculosis.  
The three reports in the RVCT form are  
· Not necessarily completed for all patients 
· Not completed all at one time.  
 
The following table provides a description of each report, for whom it is completed, and when it is 
completed.  
Note: It is strongly recommended that the hard copy of the RVCT form be completed by a health care  
provider and maintained in the TB patient’s medical record in a secured (locked) area. 
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The Three Reports Comprising the RVCT Form 
Report of Verified Case of Tuberculosis 
· Includes data about patient demographics, laboratory results, and risk associated with TB 
· Complete for all patients with a verified case of TB disease 
· Complete over time (evaluation process and treatment) as the information from the patient, the 
laboratory reports, and medical records become available 
Page 1 
(Items 1 – 16) 
 
Page 2 
(Items 17 – 25) 
 
Page 3 
(Items 26 – 37) 
Initial Drug Susceptibility Report  
(Follow Up Report - 1) 
Case Completion Report  
(Follow Up Report - 2) 
· Includes genotyping information and 
drug susceptibility testing results 
· Complete for all patients who had a 
positive culture result for 
Mycobacterium tuberculosis complex 
· Do not complete for patients with 
negative culture or no results for 
culture 
· Complete after susceptibility test 
results are received 
· Includes treatment outcomes collected 
· Complete for all patients who were alive when TB 
was diagnosed 
· Complete after treatment ends; the case completion 
report is due no later than 2 years after the initial 
RVCT 
Page 1 
(Items 38 – 40) 
Page 1 
(Items 41 – 46) 
 
Page 2 
(Items 47 – 49) 
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RVCT Items 
The revised RVCT form includes 49 items. The characteristics are varied; for example, 
· Some items include one variable response  
· Some items include more than one response (e.g., Items 3 and 4) 
· Each item is delineated in its own box 
· Some boxes are grouped together in larger boxes to visually and logically organize the space 
Items are not necessarily listed in the order in which you might receive the information
Data are entered on the RVCT form in several ways:  
1. Writing in dates and other numbers (e.g., Items 1, 2, and 3) 
2. Checking boxes (e.g., Items 9, 10, and 11) 
a. Select one 
b. Select all that apply 
3. Writing in specific information (e.g., Items 12, 14) 
4. Writing in comments (e.g., page 3, Follow Up Report–1, or Follow Up Report–2) 
Unknown Dates  
There are several items that include dates. When entering dates on the form, use “99” for an unknown 
month or day, and “9999” for an unknown year. This may vary from what will be entered into a computer 
software program. 
· 03  99  2009 – for March, unknown day, in 2009 
· 99  99  2009 – for unknown month and day in 2009 
· 01  02  9999 – for January 2, in a year that is unknown 
Note: For each item that includes dates, read the instructions carefully about entering month, day, and 
year. Some items (e.g., Date Reported, Item 1) require that the actual month and year always need to be 
entered. For those items, the actual month (not 99) should be entered, and the actual year (not 9999) 
should be entered. 
 
Pending vs. Unknown Information  
Leave the item blank if the information requested is pending (or missing). If a valid value cannot be 
determined and there is no check-box labeled Unknown, write the word Unknown inside the box that 
encloses the numbered item. This unknown notation will help the person entering the data in the software 
to know that the person who completed the form attempted to collect the information but was not able to 
do so. The data entry person will thus be better able to distinguish between data that are unknown and 
data that are pending (missing). CDC encourages active surveillance or collection of all applicable 
information. Therefore “unknown” information should be rare. 
 
Updating of Forms 
It may be necessary to update RVCT forms if a case is reopened (e.g., a patient who had been lost to 
follow-up is found) or if previously unavailable information is obtained. CDC recommends highlighting 
such changes on the hard copy to facilitate data entry into the software system designated by your 
jurisdiction. When updated data are entered in an electronic record, the new data will automatically 
overwrite the old data. 
 14 
Additional Reporting Forms 
If the reporting area has its own TB case reporting form and uses it to complete the RVCT variables, the 
staff should carefully review the RVCT variables and the instructions in this document to ensure that 
variables on the reporting area’s form match those on the RVCT form. 
Data Entry and Security 
Data obtained from RVCT forms are entered in the software system designated by your jurisdiction and 
then transmitted electronically to CDC.  
Data security is the responsibility of the state or local health department. Completed RVCT forms 
should never be sent to CDC.  
Access to the RVCT forms and data entry software should be restricted to individuals authorized to 
perform TB surveillance activities. Hard copies should be stored in a secured (locked) area. Access to the 
approved data entry software and local databases should be controlled through the use of a local user 
identification (user ID) and password. All other electronic surveillance files should also be protected with 
passwords known only to designated surveillance staff. 
Patient Confidentiality 
Case numbers must not include personal identifiers. Do not use names, initials, Social Security 
numbers, addresses, telephone numbers, or other information that could identify a patient. 
Because of the sensitive nature of some of the data collected, CDC has provided an Assurance of 
Confidentiality for the expanded surveillance system. Information on the RVCT forms and in the TB 
surveillance databases that would permit identification of any individual will be held in confidence and 
will not be released without the consent of the individual, in accordance with sections 306 and 308(d) of 
the Public Health Services Act (42 U.S.C. 242k and 242m). 
Local patient identifier information, although collected by state and local health departments, is not 
reported to CDC. Surveillance information reported to CDC is used for statistical and analytic summaries 
in which no individual can be identified and for special investigations of the natural history and 
epidemiology of TB.  
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What Is New in the RVCT 
The RVCT form has items that are either new or revised from the previous RVCT that was published in 
1993. To help orient previous RVCT users to the new items, the table of contents (at the beginning of this 
document) indicates which items are new, revised, or unchanged. 
The RVCT State Case Number (item 3), also known as the RVCT number, has been standardized by 
adding a 4-digit code for year and a 2-character (alpha) code for state (or jurisdictional code for 
jurisdictions that are not states) to the 9-character alphanumeric local identifier, so that each state case 
number is unique for year and state. The additions to the State Case Number will help when trying to 
identify a TB patient who has been transferred from one health jurisdiction (e.g., state) to another, and 
when trying to link TB cases (e.g., recurrences, contact investigations). 
 
New and Updated Variables
Eleven new variables were added to improve data collection. These variables (items) are indicated in the 
table below. 
New Variables in the Revised RVCT 
Item # New Variables 
5 Count status 
 
14 Pediatric TB patients 
21 Nucleic acid amplification test 
22B Initial chest CT scan or other chest imaging study 
24 Interferon gamma release assay 
25 Primary reason evaluated for TB disease 
34 Additional TB risk factors 
35 Immigration status 
38 Genotyping accession number 
42 Moved 
45 Reason therapy was extended for more than 12 months 
A new variable called Count Status (item 5) was added to separate counted and noncountable TB cases. 
Data can now be collected on noncountable TB cases to help identify specific cases for analysis and help 
measure TB morbidity and case management burden. Noncountable cases are verified TB cases that 
cannot be counted because they do not meet the surveillance definition of a countable case. 
 16 
Additional new variables include TB risk factors, such as diabetes, end-stage renal disease, 
immunosuppressive therapy, and the use of tumor necrosis factor-alpha antagonists. 
Other variables have been updated to reflect the changing field of TB epidemiology and to collect more 
accurate data on TB cases. Modified variables include the addition of dates of tuberculin skin testing 
(item 23) and of specimen collection for other diagnostic tests, along with result dates by laboratory type 
(items 17–21 for smear and culture results). 
Recurrences of TB 
The new variable, Count Status (item 5), allows data collection on the recurrence (more than one separate 
and distinct episode) of TB. Most recurrences occur within 6–12 months after the completion of therapy. 
For surveillance purposes, a description of how this is counted is illustrated in the following table. 
Counting Reported TB Cases 
A patient may have more than 1 discrete (separate and distinct) episode of TB disease 
TB Disease Recurs  
Within a Consecutive 12-month Period 
After the Patient Completed Therapy 
TB Disease Recurs  
More Than 12 Months  
After the Patient Completed Therapy 
Recurrence is considered the same episode (count 
only 1 episode as a case for that year; within a 12-
month period, not calendar year).  
Recurrence is considered a separate episode. 
Do not count as a new case. Count as a new case. 
More information about recurrences of TB is provided in Case Number (item 3). 
 
Overview of the RVCT Instructions 
The RVCT instructions provide information on how to complete the 49 items on the RVCT form. The 
instructions provide details about each item, explain the nuances of how to answer the items, and also 
provide examples to illustrate how to apply the instructions for entering data for a TB case.  The 
instructions are available in two formats.  
· The Report of Verified Case of Tuberculosis Instruction Manual (this manual) 
This document includes only the instructions (i.e., the exercises are not included) for each item on 
the RVCT. It can be used as a reference tool by those who complete the RVCT.  For downloading 
the RVCT Instruction Manual from the internet, see the section below on “Additional RVCT 
Materials.”  
· The Report of Verified Case of Tuberculosis Self-Study Modules  
In the modules, the instructions are integrated with exercises (study questions and case studies). 
This provides an opportunity to practice applying the instructions to life-like situations. For more 
information, see the section below on “Additional RVCT Materials.”  
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RVCT Training Materials 
To help health care staff learn how to accurately complete the RVCT the following training materials 
have been developed:  
· RVCT Self-Study Modules Participant Manual 
· RVCT Self-Study Modules Facilitator Manual 
· RVCT Instruction Manual (this manual, it includes instructions only) 
· RVCT Self-Study Modules Exercises (exercises only) 
· RVCT Materials Description 
· RVCT Materials CD ROM 
RVCT Self-Study Modules 
The Report of Verified Case of Tuberculosis Self-Study Modules are described below.  
 
· RVCT Self-Study Modules 
The modules consist of the following components: 
o Instructions for how to complete each item on the RVCT (the same instructions as are in 
this manual) 
Each item in the RVCT has detailed instructions that explain how to complete the item. It is 
very important to read the instructions for an item before answering the study 
questions. The instructions provide information on how to interpret the items and options, 
and provide examples that illustrate how to answer in specified situations. 
o Exercises 
The instructions for each item are followed by exercises that will help you apply the 
instructions to life-like situations and practice completing the RVCT.  
The modules can be used in the following ways: 
1. For individuals to learn in a self-study format 
Health care workers can use the modules according to their needs  
· Working through them at their own pace  
o Completing the whole set of modules without interruption  
o Completing one module at a time (e.g., one module per day) 
· Using the modules as a reference  
2. As part of a 2-day facilitator-led training course 
The self-study modules can be used as part of a training course that is led by a facilitator.  
· Participants work through the modules 
· Facilitators lead group discussions about the instructions and the exercises, and engage 
the participants in learning how to use the RVCT 
A facilitator’s guide is available that includes information on the best way to teach the RVCT 




Continuing education units are available free of charge for the RVCT Self-Study Modules. For more 





(page 1 of 3) 
Items 1 – 16 
 
The RVCT report includes the first three pages of the RVCT data collection form. Complete this report 
for all patients with a verified case of TB disease.  Page 1 of the RVCT report provides instructions for 





1. Date Reported 
 
Primary Purpose: Case management. Data are used to determine when the health department or 
counting authority was first notified that a person may have TB. This is important in contact 
investigations. 
Note: Item 1 requires that the actual month and year always be entered. The actual month (not 99) 
should be entered and the actual year (not 9999) should be entered. 
Description Comment 
Month, day, and year 
(e.g., 01/17/2009) 
Date that a health department (e.g., 
local, county, state) first suspected 
that the patient may have TB. 
or 
Date the health department received 
notification (verbal or written) from 
a health care provider that a patient 
was suspected of having TB. 
If the day is unknown, enter 99 as the 
default value (e.g., 01/99/2009).  
In this item, the actual month and 
year always need to be entered. Do 
not use 99 for the month or 9999 for 
the year.  
 
Comment: Date Reported  
If the patient had a previous diagnosis of tuberculosis, Date Reported applies to the current TB episode. 
Note:  On the form and throughout this document, the term state is used to refer to the reporting  
jurisdiction (or count authority), though all jurisdictions are not states. 
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Comparison of  
Date Reported (Item 1), Date Submitted (Item 2), and Date Counted (Item 6) 
 
There is frequently a lot of confusion between Date Reported (it 1), Date Submitted (item 2), and  Date 
Counted (item 6). The following information describes the differences in these three items. 
 
Summary of Events for  


















Comment: Sequence of dates 
The Date Reported (item 1) usually occurs before the Date Submitted (item 2). But sometimes they can 
occur on the same date. The Date Submitted usually occurs before the Date Counted (item 6). But all 3 
dates could occur on the same date if the count authority determines that it is a case of TB on the same 
day as the Date Reported and Date Submitted.  
Comment: Who determines the dates 
In most reporting areas (e.g., state), the state health department has count authority and reviews the 
RVCT to determine whether to officially count the case (Date Counted). However, a few states have 
granted local or county health departments count authority. In these states, the local or county health 
departments determine the Date Counted (see Date Submitted [item 2] and Date Counted [item 6]). 
 
 Summary of Date Reported, Date Submitted, and Date Counted 
 
Type of Date Who/What  Description of Action 
Date Reported (item 1) TB suspect Reported to the health department (either by the health 
department itself or another health care provider) 
Date Submitted (item 2) RVCT form Submitted to the reporting area  (e.g., state health 
department) 
Date Counted (item 6) TB Case Counted as a case of TB (by the count authority) 
Dat  Reported (I m 1) 
 




· Date the health department receives notification (verbal or written) from a health care provider 
that a patient is suspected of having TB 
 
Often, an RVCT is created by a local or county health department because this is the level at which TB 
is first suspected, and that also determines the Date Reported.  
Date Submitted (Item 2) 
· Date that the RVCT was submitted to the reporting area (e.g., state health department) 
 
 
§  Date Counted (Item 6) 
· Date that the count authority (usually the state health department, but may be another designated 
authority) reviewed the RVCT and determined whether to officially count the case. The count 
authority determines the Date Counted. 
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Comment: Date Reported 
Often, an RVCT is created by a local or county health department because this is the level at which TB 
is first suspected, and determines Date Reported (item 1). If a health care provider suspects that the 
patient may have TB and then notifies the local or county health department, the Date Reported is the 
date the health department received the report (verbal or written notification) from the health care 
provider. 
Example: Year Reported 
A case reported in December may not be counted until the next year. For example, if a case is reported 
in December 2008 but not counted until January 2009, the Year Reported for the case number would 
be 2008.   
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2. Date Submitted 
 
Primary Purpose: Programmatic function. Data are used to evaluate the time between case report and 
submission to the health department or count authority. 
Description Comment 
Month, day, and year 
(e.g., 01/17/2009) 
Date the RVCT form was submitted 
to the reporting area (e.g., state 
health department). 
If the day is unknown, enter 99 as the 
default value (e.g., 01/99/2009). 
(Note: this may vary from what will 
be entered into a computer software 
program) 
Summary of Date Reported, Date Submitted, and Date Counted 
Type of Date Who/What  Description of Action 
Date Reported (item 1) TB suspect Reported to the health department (either by the health 
department itself or another health care provider) 
Date Submitted (item 2) RVCT form Submitted to the reporting area  (e.g., state health 
department) 
Date Counted (item 6) TB Case Counted as a Case of TB (by the count authority) 
 
Comment: Date Submitted 
In most cases, the RVCT is completed by the health department (local or county) and submitted to the 
reporting area (state health department). In some locations, the RVCT may be completed and the case 
counted at the state level. 
Note: On the RVCT form and throughout this document, the term state is used to refer to the reporting  
jurisdiction (or count authority), though not all jurisdictions are states. 
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3. Case Numbers  
 
Primary Purpose: Surveillance. A unique number is assigned to each case without personal identifiers. 
Note:  On the form and throughout this document, the term state is used to refer to the reporting  
jurisdiction (or count authority), though not all jurisdictions are states. 
State Case Number   
The State Case Number is the official identification number for the case. If additional communication 
about a record is required between CDC and a reporting area, this number is used to identify the record. 
The State Case Number is commonly known as the RVCT number. 
 
City/County Case Number 
List the City/County Case Number. Every case reported, whether from a city/county or state 
surveillance system, must have a unique case number for identification purposes. 
Comment: Case Numbers 
A single case may be assigned identical City/County Case and State Case Numbers. A City/County 
Case Number may not be assigned to more than one case during a calendar year. Similarly, a State Case 
Number may not be assigned to more than one case during a calendar year.  
Note: Case numbers must not include personal identifiers. To maintain patient confidentiality, do not 
use names (either patient or provider), initials, Social Security numbers, addresses, telephone numbers, 
or other information that could identify a patient. Case numbers are transmitted to CDC and therefore 
must not include personal identifying information. 
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Assigning case numbers 
Both the State Case Number and the City/County Case Number have 15 alphanumeric characters. 
Year Reported (YYYY) State 
Code 
Locally Assigned Identification 
Number 











Example: Year Reported 
A case reported in December may not be counted until the next year. For example, if a case is reported in 
December 2008 but not counted until January 2009, the Year Reported for the case number would be 
2008.   
Note: All countable and noncountable TB cases should receive a unique case number. Documenting 
noncountable cases provides evidence of increased workload or burden to programs when cases are not 
countable. 
Note: For the purposes of the RVCT Materials, use the codes listed in the appendices. Some software 
programs used to enter data on the RVCT may NOT use the codes listed in the appendices. For 
example, the Anatomic Codes may be a drop-down item where you choose the actual site rather than 
enter a code. For more information, see instructions for the software you use. 
 
Linking State Case Numbers 
For the purposes of linking RVCT forms, you may enter as many as 2 RVCT State Case Numbers  
under Linking State Case Number.  
Under Reason for Linking Case, explain the purpose of the link by entering one of the single-digit codes 
indicated in the table below. 
· Year Reported indicates the year in 
which the case is reported (e.g., 2010). 
· Year reported is used rather than the 
year counted since there may be a lag 
between when states or city/county 
areas first suspected that the patient 
might have TB and when diagnostic 
criteria are verified. 
State Code indicates the 2-
letter postal code of the 
state reporting this case 
(e.g., GA for Georgia) (see 
Appendix D – Reporting 
Area Codes). This 
abbreviation is also known 




indicates the 9 
numbers/characters that are 
locally assigned to identify 
this RVCT. 
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Rationale for Linking RVCT Forms 
Reason Code Reason for Linking Case 
1 Recurrence  
or  
Previous diagnosis of TB 
2 Epidemiologically linked case, source case, or contact with another case 
3 Case transferred from another area 
Examples: Reasons for Linking Case 
· Reason 1 – Recurrence or previous diagnosis of TB*  
If you are completing a “recurrence” RVCT for a diagnosis of TB disease in the same patient that 
recurred within 12 months after the completion of therapy, you must enter the RVCT State Case 
Number of the original TB case under Linking State Case Number, and enter 1 as the Reason 
code.  
A previous diagnosis of TB can have occurred any time in the past.  
A patient is considered to have had a previous diagnosis of TB disease if  
o TB disease was verified in the past 
or  
o The patient completed therapy (even if the case-to-case interval is within 12 months)* 
or  
o The patient was lost to supervision for more than 12 months and now has verified disease 
again.  
If a patient had previous TB disease anytime in the past, enter 1 as the Reason code. 
· Reason 2 – Epidemiologically linked case, source case, or contact with another case 
If you have identified the source case for the TB case for which you are completing the RVCT 
and the RVCT State Case Number of the source case is available, enter the RVCT State Case 
Number of the source case under Linking State Case Number, and enter 2 as the Reason code. 
Another example of an Epidemiologically linked case is transmission of TB from one family 
member to another.  
· Reason 3 – Case transferred from another area 
If you are managing a TB case counted by another area, enter the RVCT State Case Number of 
the case from the transferring jurisdiction under Linking State Case Number, and enter 3 as the 
Reason code. Transfer cases are linked when the patient is in therapy and transfers from another 
reporting area. The patient could have moved or appeared at a health department in another area 
after being lost to follow-up. 
 
*Note: Recurrent cases within 12 months of completion of therapy should be considered noncountable,  
  regardless of whether the initial and the subsequent genotypes are the same or are different.  
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Comment: Recurrence of TB  
A recurrence (more than one separate and distinct episode) is defined as the return of TB disease in a 
patient whose specimen result can be described by either of the options listed in the table below.  
Specimen Results Required for Recurrence of TB Disease 
Option Specimen Result 
at Time of 
Diagnosis 
Specimen Result 





Option 1 Culture positive Becomes and 
remains 
culture negative  
Becomes culture positive for M. 
tuberculosis complex, or clinical or 
radiologic evidence is consistent with 
TB disease. 
Option 2 Smear negative or 
culture negative  
(TB diagnosis is based 
on clinical evidence) 
Remains smear 
negative or culture 
negative 
Becomes culture positive for M. 
tuberculosis complex, or clinical or 
radiologic evidence is consistent with 
TB disease. 
The process for reporting a recurrence of TB is illustrated in the table below. 
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Process for Reporting a Recurrence of TB 
A person may have more than 1 discrete (separate and distinct) episode of TB disease 
TB Disease Recurs  
Within a Consecutive 12-month Period 
After the Patient Completed Therapy 
TB Disease Recurs  
More Than a Consecutive 12-month 
Period 
After the Patient Completed Therapy 
Recurrence is considered the same TB episode 
(count only 1 episode as a case for that year; within 
a 12-month period, not calendar year).  
Recurrence is considered a separate TB episode.  
Do not count as a new case. Count as a new case. 
Count only one TB episode as a case for that year 
(within a 12-month period, not calendar year). 
No updates are needed for the initial RVCT form 
because therapy was completed at least 12 months 
before the recurrence was diagnosed. 
Complete 2 RVCT Forms 
(Only the initial TB episode is countable) 
1)  For the initial countable TB episode: 
a) Ensure that Date Therapy Stopped (item 
43) reflects a date of therapy completion 
before TB recurrence. 
b) Do not update any other variables on the  
RVCT form. 
2)  For the noncountable TB episode:  
a) Use a new RVCT State Case Number 
(item 3), that is, a number that is different 
from the State Case Number on the 
countable TB episode form. 
b) Enter the countable TB episode State Case 
Number under Linking State Case 
Number and specify as Reason 1 – 
Recurrence or previous diagnosis of TB so 
that these 2 forms can be linked. 
c) Check Verified Case: Recurrent TB 
within 12 months for the variable Count 
Status (item 5). 
d) Complete the remainder of the RVCT form as 
appropriate. This case will not be included in 
the TB case count of the reporting area, but will 
provide valuable information on recurrences 
within 12 months after the completion of 
therapy. This allows electronic linkage 
between the countable TB episode and data 
associated with the recurrence.  
Complete 2 RVCT Forms  
(Both TB episodes are countable) 
1)  For the initial countable TB episode: 





2)  For the second countable TB episode: 
a.) Enter a new RVCT State Case Number (item 
3), different from the State Case Number on 
the initial RVCT form. 
b.) Enter the initial RVCT State Case Number, 
if available, under Linking State Case 
Numbers and specify as Reason 1 – 
Recurrence or previous diagnosis of TB so 
that these 2 forms can be linked. 
c.) Check Count as a TB Case for Count Status 
(item 5). Do not check Verified Case: 
Recurrent TB ≤ 12 months. 
d.) Complete the remainder of the RVCT form as 
appropriate. This TB case will be counted 
because, for surveillance purposes, it is 
considered a separate TB episode. Also, it will 
provide valuable information on recurrences 
more than 12 months after the completion of 
therapy.  This allows electronic linkage 
between the initial TB episode and the new 
TB episode.  
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4. Reporting Address for Case Counting   
 
Primary Purpose: Programmatic function. Data are used to document the patient’s address from the 
state or jurisdiction that is counting the case.  
The Reporting Address for Case Counting is usually the City, County, and ZIP Code of the patient’s 
residence at the time of diagnosis. But there are exceptions to this, which are indicated in the Guidelines 
to Determine Reporting Address for Case Counting table below. To the extent possible, the address for 
case counting should represent the home address (whether permanent or temporary) of the patient. 
Recommendations for counting reported TB cases are outlined in Appendix B – Recommendations for 
Reporting and Counting Tuberculosis Cases. 
Note: For countable and noncountable cases, enter the TB patient’s address from the state or 
jurisdiction that is reporting and documenting the case.  





Yes Patient lives within the city limits  
No Patient does not live within the city limits 
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Guidelines to Determine Reporting Address 





























































Migrant, immigrant (i.e., 
resident alien living in the 
United States), U.S. military 
personnel, and other 
transient persons  
 
Count in the area in which he/she lived 
at the time that the TB diagnostic 
evaluation was performed or initiated 
Enter city, county, 
and ZIP Code 
where he/she lives 
at the time of 
diagnosis 
Homeless or does not have 
a fixed residence 
Count in area in which he/she was 
living at the time that the TB diagnostic 
evaluation was performed or initiated 
(e.g., the locality of the shelter or area in 
which the patient was living) 
Enter city, county, 
and ZIP Code of 
that locality 
Resident of correctional 
facility at time of TB 
diagnosis (e.g. local, state, 
federal, military) 
Count in area in which the correctional 
facility is located at the time that the TB 
diagnostic evaluation was performed or 
initiated 
Enter city, county, 
and ZIP Code of 
the correctional 
facility 
Resident of long-term care 
facility at time of TB 
diagnosis 
Count in area in which the long-term 
care facility is located at the time that 
the TB diagnostic evaluation was 
performed or initiated 
Enter city, county, 




Receives a new TB 
diagnosis in the community 
that he/she considers home 
Count in the morbidity count for that 
area  
Enter city, county, 
and ZIP Code of 
residence 
Receives a new TB 
diagnosis, but is an out-of-
area resident and will 
return home for treatment  
Count in morbidity count of their home 
area 
Enter city, county, 
and ZIP Code of 
his/her home area  
Receives a new TB 
diagnosis, but is an out-of-
area resident and 
completes therapy where 
he/she was diagnosed  
Count in morbidity count where they 
live at the time that the TB diagnostic 
evaluation was performed or initiated 
Enter city, county, 
and ZIP Code 
where he/she lives 
at the time of 
diagnosis 
Staying in a community 
only for TB diagnosis and 
hospitalization  
Count in the morbidity count of his/her 
area of residence, not the community 
where diagnosed and hospitalized.  
 
Communication between health 
departments may be necessary to decide 
which jurisdiction will count the case. 
Enter city, county, 
and ZIP Code of 
























Foreign visitor who receives a 
TB diagnosis in the United 
States, is receiving anti-TB 
therapy, and has been, or plans 
to remain, in the country for  
90 days or more 
Count in the area in which he/she lived 
at the time that the TB diagnostic 
evaluation was performed or initiated 
Enter city, county, 
and ZIP Code of  
current residence 
Foreign visitor who receives a 
diagnosis of TB in the United 
States, is receiving anti-TB 
therapy, and has been, or plans 
to remain, in the country for 
less than 90 days 
Should not be included in the count of 
TB cases in the United States.  
Enter city, county, 
and ZIP Code of  
current residence 
Receives a diagnosis of TB 
before arriving in the United 
States 
Should not be included in the count of 
TB cases in the United States. Submit it 
as a noncountable case because the case 
is considered to have occurred in 
another country, even if therapy is 
continued or completed in the United 
States. 
Enter city, county, 
and ZIP Code of  
current residence 
Comment: People Entering the United States  
For additional information on immigrants, refugees, permanent resident aliens, border crossers, and 
foreign visitors see Appendix B – Recommendations for Reporting and Counting Tuberculosis Cases. 
 
Guidelines for classifying transfer cases 
A total of 60 areas are responsible for reporting cases of TB to CDC. These reporting areas are the 50 
states, the District of Columbia, New York City, Puerto Rico, American Samoa, the Federated States of 
Micronesia, Guam, the Republic of the Marshall Islands, the Commonwealth of the Northern Mariana 
Islands, the Republic of Palau, and the U.S. Virgin Islands. Because of the additional (follow-up) 
reporting requirements for expanded surveillance, specific instructions are necessary for the completion 
of forms for patients who move within a reporting area and for those who move from one reporting area 
to another during treatment. 
· To minimize the number of TB patients who are lost to follow-up, update the patient’s street 
address regularly during treatment.
· Periodically, ask patients whether they anticipate moving so that arrangements can be made to 
maintain continuity of care and ensure submission of follow-up RVCTs. Encourage patients who 
anticipate moving to report their new address, so that necessary patient information can be 
forwarded to health care providers, and to the TB control program in the area to which the patient 
is moving. Health departments should use the National TB Controllers Association (NTCA) 
Interjurisdictional Tuberculosis Notification and Follow-up forms to notify TB control program 
staff in another reporting area that a TB patient is moving to their area.  
Communication between TB control programs to ensure continuity of care and submission of 
follow-up reports regarding a patient who is moving from one area to another should be 
conducted as efficiently and securely as possible (e.g., telephone, e-mail, fax, express courier).
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Example: Moves within the reporting area  
If a TB patient with an existing RVCT record moves within the reporting area that initially reported the 
case (e.g., from county A to county B within a state), communication between county or local health 
departments may be all that is necessary to maintain continuity of care and ensure submission of follow-
up reports for the RVCT. In this instance, the responsibility for following the case to closure and for 
submitting follow-up reports to CDC remains with the initial reporting area (e.g., the state). To avoid 
duplicate case reporting, the state may need to coordinate the submission of forms with counties A and B 
so that only one counted case is submitted. County B can complete a noncountable RVCT to gather 
surveillance data and demonstrate patient management.
 
Example: Moves from one reporting area to another  
If a TB patient with an RVCT record moves from one reporting area to another (e.g., from state A 
[Louisiana] to state B [Georgia]), the responsibility for submitting follow-up reports to CDC remains with 
the state or reporting area that initially reported the case to CDC and counted it (e.g., state A [Louisiana]). 
This responsibility remains with the initial area only for surveillance purposes (i.e., to minimize 
duplication of case reports and to simplify the reporting of the final disposition of the case). In other 
words, state B will conduct case management and follow-up and will then share follow-up surveillance 
information with state A, which will officially submit follow-up information to CDC. State B is 
encouraged to complete an RVCT for a noncountable transfer case. 
 
To facilitate this process, state A should send the NTCA Interjurisdictional Tuberculosis Notification and 
Follow-up forms to state B and should inform state B that the case has been reported to CDC and 
counted. State A should also inform state B of the surveillance information that has been reported to CDC 
and the information that will need to be collected by state B and forwarded to state A for reporting to 
CDC. State B should use the forms to inform state A when or if the TB patient has been located and to 
inform state A of the final disposition of the case (e.g., patient completed therapy, patient died). 
Comment: Definition for Migrant/seasonal worker 
A migrant or seasonal worker is a person who is required to be absent from a permanent place of 
residence for the purpose of seeking employment or who may vary their employment for the purpose of 
remaining employed while maintaining a permanent place of residence. 
Examples: Migrant/seasonal worker 
· Migratory agricultural worker 
· Seasonal agricultural worker 
· Migrant factory worker 
· Migrant construction worker 
· Migrant service industry worker 
· Migrant sporting worker (e.g., horse racing, dog racing) 
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Comments: Definitions for Homeless 
There are many definitions for homeless (National Coalition for the Homeless).  A homeless  
person may be an individual who has 
1. No fixed, regular, and adequate nighttime residence  
and 
2. A primary nighttime residence that is 
a. A supervised publicly or privately operated shelter designed to provide temporary living  
accommodations, including welfare hotels, congregate shelters, and transitional housing for 
the mentally ill  
or 
b. An institution that provides a temporary residence for individuals intended to be  
institutionalized 
or 
c. A public or private place not designated for, or ordinarily used as, a regular sleeping  
accommodation for human beings. 
A homeless person may also be defined as a person who has no home (e.g., is not paying rent, does not 
own a home, and is not steadily living with relatives or friends). Persons in unstable housing situations 
(e.g., alternating between multiple residences for short stays of uncertain duration) may also be 
considered homeless.  
A homeless person may be a person who lacks customary and regular access to a conventional dwelling 
or residence. Included as homeless are persons who live on streets or in nonresidential buildings. Also 
included are residents of homeless shelters and shelters for battered women. Residents of welfare hotels, 
and single room occupancy (SRO) hotels could also be considered homeless. In the rural setting, where 
there are usually few shelters, a homeless person may live in non-residential structures, or substandard 
housing, or with relatives. Homeless does not refer to a person who is imprisoned or in a correctional 
facility.  
Note: The homeless category is limited to living conditions in the United States and does not apply to 
living in refugee camps outside the United States. 
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5. Count Status 
 
Primary Purpose: Surveillance. Data are used to document the number of TB cases and disease trends 
that occur in the United States; to determine the burden of TB disease within all areas; and to serve as a 
basis for allocation of resources, including funding.  
In addition to requiring the completion of an RVCT form for all counted TB cases, CDC recommends 
that a reporting area complete an RVCT form for TB patients being managed in that area but counted by 
another reporting area, even though the area providing case management cannot include such cases in its 
annual morbidity count. This will help indicate the burden of disease within all areas. Moreover, CDC 
recommends that a reporting area complete an RVCT form for TB recurrences which are within 12 
months after the completion of therapy, which are also not included in the annual morbidity count. For 
CDC guidelines on counting TB cases, see Appendix B – Recommendations for Reporting and Counting 
Tuberculosis Cases. 
Countable TB Case 
Option Description 
Count as a TB case Officially counted as a TB case, by the jurisdiction with count authority  
(usually state health department).  
For a diagnosis to be counted as a TB case, it must meet the following criteria: 
1. Is a verified case of TB (see Case Definition for Tuberculosis below) 
2. Confirmed that it is NOT counted by another area  
3. Meets surveillance definition and is NOT a recurrent case (within 12 
months of completion of therapy) of TB 
Note: A case of TB is defined as an episode of TB disease in a person meeting the laboratory or 
clinical criteria for TB as defined in Appendix A – Tuberculosis Case Definition for Public Health 
Surveillance for criteria. 
Note: Communication between TB control programs to ensure continuity of care and submission of 
reports regarding a patient who is moving from one area to another should be conducted as securely 
and efficiently as possible (e.g., telephone, e-mail, secure fax, express courier). 
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Noncountable TB Case 
 
If the verified TB case was not counted by the jurisdiction with count authority, select one option to 




Counted by another 
area (e.g., county, 
state, or counting 
authority) 
TB case counted by another U.S. area 
such as a state or other counting 
authority (e.g., transfer in) 
Typically, diagnostic workup has 
been completed, and patient is 
receiving anti-TB medications. 
 
Count authority includes the U.S.  
Territories, U.S. Island Areas, and 
U.S. Outlying Areas. 
 
TB treatment 
initiated in another 
country 
TB case counted by another  
country  
Under Specify, enter the country where 
TB treatment was initiated.  
It may be difficult to verify whether 
a case has been counted in another 
country because typically, 
diagnostic work-up may have been 
completed and patient is receiving 
anti-TB medications. 
Recurrent TB 
within 12 months 
after completion of 
therapy  
Complete a new RVCT form because of 
recurrence within 12 months after the 
completion of therapy (not when 
therapy was initiated) 
Completing a new RVCT form 
allows the RVCT forms to be linked 
and information on the recurrence 
to be collected. 
 
Comment: 12 months 
The term 12 months refers to 12 consecutive months, not a calendar year.  
 
Comment: U.S. Territories, U.S. Island Areas, and U.S. Outlying Areas 
Counted by another area or counting authority includes the U.S. Territories, U.S. Island Areas, and U.S. 
Outlying Areas (e.g., Puerto Rico, American Samoa, Federated States of Micronesia, Guam, Republic of 
the Marshall Islands, Commonwealth of the Northern Mariana Islands, Republic of Palau, U.S. Virgin 
Islands). These independent countries have Compacts of Free Association with the United States; under 
these compacts, the countries are fully sovereign in domestic and foreign affairs, but give responsibility 
for their health, education, defense, and other essential operations to the United States.  
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Counting Recurrent TB Cases 
A person may have more than 1 discrete (separate and distinct) episode of TB disease 
TB Disease Recurs  
Within a Consecutive 12-month Period 
After the Patient Completed Therapy 
TB Disease Recurs  
More Than 12 Months  
After the Patient Completed Therapy 
Recurrence is considered the same TB episode 
(count only 1 episode as a case for that year; within 
a 12-month period, not calendar year).  
Recurrence is considered a separate TB episode.  
Do not count as a new case. Count as a new case. 
Note: Recurrent cases within 12 months of completion of therapy should be considered noncountable, 
regardless of whether the initial and the subsequent genotypes are the same or are different.  
 
Comment: People Entering the United States  
For additional information on immigrants, refugees, permanent resident aliens, border crossers and 
foreign visitors see Appendix B – Recommendations for Reporting and Counting Tuberculosis Cases. 
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6. Date Counted 
 
Primary Purpose: Surveillance. Data are used by the count authority to tally the official TB case count 
for the month, quarter, and year. 
 
Description Comment 
Month, day, and year 
(e.g., 01/17/2009) 
Date that the responsible count 
authority (usually the state health 
department, but might be another 
designated authority)   
· Reviewed the RVCT 
· Verified the case as TB 
and 
· Included it in the official TB 
case count 
If the day is unknown, enter 99 as the 
default value (e.g., 01/99/2009). 
Summary of Date Reported, Date Submitted, and Date Counted 
 
Type of Date Who/What  Description of Action 
Date Reported (item 1) TB suspect Reported to the health department (either by the health 
department itself or another health care provider) 
Date Submitted (item 2) RVCT form Submitted to the reporting area  (e.g., state health 
department) 
Date Counted (item 6) TB case Counted as a Case of TB (by the count authority) 
 
Comment: Pending results 
Suspected cases for which bacteriologic results are pending or for which verification of disease is 
questioned for any reason should be counted only after they are determined to be verified TB cases. This 
could mean that a case reported in one year may not be counted until the following year. 
Example: Date Counted 
If a case is reported to the health department in December 2008, but bacteriologic or clinical evidence of 
TB is not available until January 2009, the case should be counted in January 2009 (when TB disease was 
verified), not in December.
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7. Previous Diagnosis of TB Disease  
 
Primary Purpose: Case management and surveillance. Data are used to evaluate the patient’s response 




Yes Patient has received a previous 
diagnosis of TB disease. 
Do not enter a previous diagnosis of latent 
TB infection (LTBI). 
If you selected Yes, enter the year of 
previous diagnosis of TB disease 
(e.g., 1985). 
 
If the patient had more than 1 previous 
episode of TB disease, enter the year of 
the most recent previous episode. 
No Patient has not received a previous 
diagnosis of TB disease. 
Comments: Yes  
A patient is considered to have had a previous diagnosis of TB disease if  
· TB disease was verified in the past 
or  
· The patient completed therapy for TB disease (even if the case-to-case interval is within 12 
months) 
or  
· The patient with TB disease was lost to supervision for more than 12 months and now has 
verified TB disease again.  
Note: Recurrent cases within 12 months of completion of therapy should be considered noncountable, 
regardless of whether the initial and the subsequent genotypes are the same or are different.  
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If the patient had a previous episode of TB that was reported to U.S. surveillance, you should, for the 
purposes of linking RVCT forms 
· Contact the state in which the case was counted to ask for the most recent previous diagnosis 
· Enter the most recent previous RVCT State Case Number for this case under Linking State 
Case Number (item 3) 
· Enter the code for the Reason linking is desired (e.g., enter 1 for recurrence or previous diagnosis 
of TB) 
Documentation of Previous Diagnosis of TB Disease 
Often, TB disease is confused with latent TB infection (LTBI), which should not be coded as previous TB 



















When written documentation is not available, oral report of 
a previous episode of TB disease is acceptable (e.g., 
medications taken, length of course of medication, results 
of sputum smear examination). 
Written Documentation  
Written documentation of the previous episode of TB 
disease is ideal. However, if the TB disease episode 
occurred years ago or in another location (e.g., other 
country), obtaining written documentation may be difficult. 
 
1st Priority  
Written Documentation 
If written documentation is 





8. Date of Birth  
 
Primary Purpose: Surveillance. Data are used to document patient demographic information. 
Description Comment 
Month, day, and year 
(e.g., 04/26/1968) 
Patient’s complete date of birth 
should be entered (i.e., values 
should be entered for month, day, 
and year). 
Some societies or cultures throughout 
the world do not document the day, 
month, or even the year of birth. 
 
If the day is unknown, or the month 
and the day are unknown, enter 99 as 
the default value (e.g., 04/99/1968 or 
99/99/1968). 
 
If the month, day, and year of birth 




9. Sex at Birth   
 





Male The biological sex of the TB patient was Male at birth. 









10. Ethnicity   
 





Hispanic or Latino Patient considers himself or herself 
Cuban, Mexican, Puerto Rican, 
South or Central American, or of 
other Spanish culture or origin, 
regardless of race. 
Some patients prefer the term 
“Spanish origin” to Hispanic or 
Latino. 
Not Hispanic or  
Latino 
Patient does not consider himself or  
herself Hispanic or Latino. 
 
Comment: Self-identity or self-reporting  
The response to this item should be based on the patient’s self-identity or self-reporting.  
It should not be based on appearance or surname. 
 
Example: Not Hispanic or Latino but has a Hispanic name 
A patient may have a Hispanic name, but may not be Hispanic or Latino. For example, if a woman who is 
not Hispanic marries a Hispanic man, she may self-report as “Not Hispanic or Latino.” Similarly, people 




Primary Purpose: Surveillance. Data are used to detect high-risk groups for TB by race. 
Option 
(select one or more) 
Description 
American Indian or 
Alaska Native 
Patient has origins in any of the original peoples of North and South 
America (including Central America).  
Asian Patient has origins in any of the original peoples of the Far East, Southeast 
Asia, or the Indian subcontinent (e.g., including Bangladesh, Cambodia, 
China, India, Indonesia, Japan, Korea, Malaysia, Nepal, Pakistan, the 
Philippine Islands, Thailand, and Vietnam). 
Black or African 
American 
Patient has origins in any of the black racial groups of Africa. 
Native Hawaiian or 
Other Pacific Islander 
Patient has origins in any of the original peoples of Hawaii, Guam,  
American Samoa, or other Pacific Islands. 
White Patient has origins in any of the original peoples of Europe, the Middle 
East, or North Africa. 
 
Comment: Self-identity or self-reporting  
The response to this item should be based on the patient’s self-identity or self-reporting.  
Therefore, patients should be offered the option of selecting more than one racial designation.  
Comment: Asian or Native Hawaiian or Other Pacific Islander 
If you selected Asian or Native Hawaiian or Other Pacific Islander, use the National Electronic 
Disease Surveillance System (NEDSS) Person Race Categories to complete Specify. The chart below 
indicates who is considered Asian and who is considered Native Hawaiian or Other Pacific Islander.
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National Electronic Disease Surveillance System (NEDSS) 
Person Race Categories for Asian and for  
Native Hawaiian or Other Pacific Islander* 
Asian Native Hawaiian or  






































Other Pacific Islander 
Palauan 











*From NEDSS Logical Data Model Data Dictionary: Appendix B, 1. Standardized Vocabulary, 1.4 Person Race Categories and 
Codes (http://www.cdc.gov/nedss/DataModels/NEDSS_LDM_Dictionary_II.pdf;  last updated 11-19-2001)  
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12. Country of Birth  
 
Primary Purpose: Surveillance. Data are used to determine the rate of TB among “U.S.-born” and 
foreign-born persons and to identify persons from countries with a high rate of TB. 
Note: This portion of the RVCT asks 2 questions to help classify a person based on where the person 
was born.    
· “U.S.-born.” The U.S. Census Bureau defines a “U.S.-born” person to be someone born in 1 of the 
50 states or the District of Columbia, or someone born outside the United States to at least one parent 
who was a U.S. citizen. In order to be consistent with the U.S. Census Bureau and to be able to apply 
census bureau population data to calculate TB rates, CDC uses the same definition for “U.S.-born.” 
 
· Country of birth.  In order to distinguish persons who were born in another country (whether or not 
they had a parent who was a U.S. citizen) from those who were born in the United States, this 
question simply asks to record the actual country of birth. Therefore, a patient who was born in 
France and whose father was a U.S. citizen would be “U.S.-born” and their country of birth would be 
France.   




Yes If the person was born  
· In 1 of the 50 U.S. states or 
the District of Columbia, 
or 
· Abroad to a parent who was a 
U.S. citizen. 
“U.S.-born” does not mean the same as U.S. 
citizen, and it does not necessarily mean that the 
person was born in the United States.  
 
Not all U.S. citizens (e.g., naturalized citizens) are 
“U.S.-born.”   
No If the person was born  
· Abroad  
and 
· Neither parent was a U.S. 
citizen. 
Select for any country other than the United 
States.   
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Country of birth 
Description 
Country of birth (specify) 
(e.g., United States, Mexico, 
China) 
Enter the name of the country in which the person was actually born.  
 
Fill this out for all patients (whether they were “U.S.-born” or not).  
Examples of U.S.-Born  
Patient Father Mother 
U.S.-born Description  U.S. citizen U.S. citizen 
Yes No Yes No Yes No 
Yes Born in 1 of the 50 states or the District of 
Columbia 
Yes Yes 
Yes Born in 1 of the 50 states or the District of 
Columbia 
No No 
Yes Born in another country Yes Yes 
Yes Born in another country Yes No 
Yes Born in another country No Yes 
No Born in another country No No 
Note: People born in Puerto Rico, Guam, the U.S. Virgin Islands, or the Commonwealth of the 
Northern Mariana Islands are U.S. citizens, but are only considered “U.S.-born” if they are born to a 
parent who is a U.S. citizen. 
Comment: “U.S.-born” 
If the patient was born in 1 of the 50 states or the District of Columbia, or born abroad to a parent who 
was a U.S. citizen (either the mother or father or both parents), the patient is considered “U.S.-born.”
Select Yes for “U.S.-born.” For country of birth, enter the name of the country where the person was 
actually born.  
Example: “U.S.-born” and actually born in 1 of the 50 states or the District of Columbia 
If the person was actually born in 1 of the 50 states or the District of Columbia, enter
· “U.S.-born” – Yes 
· Country of birth – United States  
Example: “U.S.-born” and actually born in another country
If the patient is born in Haiti, his mother is Haitian, but his father is a U.S. citizen, enter
· “U.S.-born” – Yes 
· Country of birth – Haiti  
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Example: “U.S.-born” and born to parents who were born in Puerto Rico, Guam, the U.S. 
Virgin Islands, or the Commonwealth of the Mariana Islands (people born in these countries are 
U.S. citizens) 
If the patient was born in Puerto Rico and both parents were born in Puerto Rico (therefore U.S. 
citizens), enter 
· “U.S.-born” – Yes 
· Country of birth – Puerto Rico 
Comment: Not “U.S.-born” and born in any country other than the U.S.  
If the patient was born in a country other than the United States to parents who were not “U.S. citizens,”
enter  
· “U.S.-born” – No 
· Country of birth – name of the country where the person was actually born 
Example: Not “U.S.-born” but born in Puerto Rico, Guam, the U.S. Virgin Islands, or the 
Commonwealth of the Mariana Islands (people born in these countries are U.S. citizens but not 
necessarily U.S.-born) 
If the patient was born in Puerto Rico and but neither parent was a U.S. citizen, enter 
· “U.S.-born” - No 
· Country of birth – Puerto Rico 
Example: Not “U.S.-born” and born to parents who are not U.S. citizens
If the patient was born in Russia and both parents are Russian citizens, enter 
· “U.S.-born” - No 
· Country of birth – Russia 
 49 
13. Month-Year Arrived in U.S. 
 
Primary Purpose: Programmatic function. Data are used to guide TB programs in developing 
strategies for TB prevention and control for persons born outside the U.S. 
 
Description Comment 
Month and year 
(e.g., 02/1975) 
When the patient first arrived in the 
United States (1 of the 50 states or 
the District of Columbia). 
Complete this item if the patient was 
born in another country.  
 
If month is unknown, enter 99 as the  
default value (e.g., 99/1975). 
 
If neither month nor year is known,  
enter 99/9999. 
Leave item blank If patient was born in 1 of the 50 
states or the District of Columbia.  
Comment: If the patient was born abroad to a parent who was a U.S. citizen 
If a patient was born abroad to a parent who was a U.S. citizen, enter the month and year that the patient 
first arrived in the United States (1 of the 50 states or the District of Columbia). 
Example: If the patient was born abroad to a parent who was a U.S. citizen 
If a patient was born in Germany to a parent who was a U.S. citizen, enter the month and year that the 
patient first arrived in the United States (1 of the 50 states or the District of Columbia). 
Example: If the patient was born abroad to a parent who was a U.S. citizen 
If a patient was born in Puerto Rico to a parent who was a U.S. citizen, enter the month and year that the 
patient first arrived in the United States (1 of the 50 states or the District of Columbia). 
 
Example: Date that a patient first arrived from another country who enters on student visa 
If a patient is a citizen from another country and comes to the United States (1 of the 50 states or the 
District of Columbia) on a student visa and returns home, and then later returns to the United States, the 
date when the patient first arrived in the United States as a student would be the date that should be 
entered, even if the patient doesn’t return for many years.  
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14. Pediatric TB Patients (<15 years old)  
 
Primary Purpose: Surveillance. Data are used to capture risk factors for guardians born in countries 
that have a high burden of TB and when pediatric patients live in TB endemic countries. 
To better capture important information about pediatric TB patients (<15 years old), this variable provides 
information on country of birth for primary guardians (or primary care givers) of the pediatric patient and 
whether the patient lived outside the United States (1 of the 50 states or the District of Columbia) for an 
uninterrupted period of more than 2 months. 
Note: Pediatric TB Patients (item 14) should be completed for all pediatric patients. For all pediatric 
patients, ask the country of birth for parents or primary guardians and whether the patient has lived 
outside the United States for >2 months consecutively.   
Complete this item for all pediatric TB patients (<15 years old). 
Description 
Country of birth for the 
primary guardians (e.g., 
mother, father, adoptive or 
foster parent, grandparent) 
Enter the names of the countries where the primary guardians were 
actually born.  
Enter as many as 2 parents or primary guardians. 




Yes Pediatric patient lived outside the United 
States (1 of the 50 states or the District of 
Columbia) for an uninterrupted period of 
more than 2 months. 
Although it may be difficult to 
determine the exact amount of 
uninterrupted time that a patient lived 
outside the United States, check Yes 
and enter the names of the countries if 
the period is believed to be more than 
8 consecutive weeks (2 months). 
No Pediatric patient did not live outside the 
United States for an uninterrupted period 
of more than 2 months. 
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Unknown It is not known whether the pediatric patient 
lived outside the United States for an 
uninterrupted period of more than 2 
months. 
Comment: Lived outside the United States 
Lived outside the United States refers to the place where a person stayed or slept most of the time, or the 
place the person considered home during the stated period. 




Enter the names of the countries where 
the pediatric patient lived. 
Enter as many as 3 non-U.S. countries in 
which the patient most recently lived for a 
total of more than 2 uninterrupted 
months. 
 
Example: Yes, Lived outside the United States in as many as 3 countries for a total of more than 2 
uninterrupted months  
From January 1 to March 15, the patient lived outside the United States  
· Lived in Zambia for 10 weeks, then 
· Returned to the United States 
 
Example: Yes, Lived outside the United States in as many as 3 countries for a total of more than 2 
uninterrupted months  
From January 1 to March 15 the patient lived outside the United States  
· Lived in Zambia for 4 weeks, then  
· Lived in South Africa for 3 weeks, then 
· Lived in Botswana 3 weeks, then 
· Returned to the United States 
Example: No, Lived outside the United States in as many as 3 countries for a total of more than 2 
months, but travel was interrupted  
From January 1 – March 15 the patient lived outside the United States  
· Lived in Zambia for 5 weeks, then 
· Returned to the United States for 2 weeks, then 
· Lived in South Africa for 5 weeks, then  
· Returned to the United States 
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15. Status at TB Diagnosis   
 






Alive Patient was alive at time 
· Laboratory results 
confirming a TB 
diagnosis (e.g., positive 
culture or nucleic acid 
amplification [NAA] 
test result consistent 
with TB) were known 
to the provider 
or 
· TB medications were 
started 
If the patient 
· Was known to be culture or NAA test result 
positive consistent with TB prior to the date of 
death but did not start TB therapy per 
ATS/CDC/IDSA guidelines, classify the patient 
as alive at TB diagnosis 
· Started empiric therapy for TB disease (per 
ATS/CDC/IDSA guidelines), but TB was not 
verified until after the patient’s death, classify 
as alive at TB diagnosis 
· Started TB therapy, regardless of laboratory or 
clinical confirmation for TB diagnosis, classify 
the patient as alive at TB diagnosis 
Dead Patient was deceased at the 
time laboratory results 
confirming a TB diagnosis 
(e.g., positive culture or 
NAA test result consistent 
with TB) were known to 
the provider 
· If diagnostic specimens were collected for 
evaluation of TB prior to death, but positive 
results to make a diagnosis of TB were not 
available until after death, and patient did not 
start TB therapy, classify as dead at TB 
diagnosis 
· If TB diagnosis was made after death based on a 
constellation of clinical and other findings (e.g., 
symptoms, TST, and imaging studies) in the 
absence of laboratory confirmation, and the 
patient did not start therapy, classify as dead at 
TB diagnosis 
· If patient was receiving treatment for latent TB 
infection at death because active TB disease was 
not suspected, and TB was diagnosed after 
death, classify as dead at TB diagnosis 
· If patient was diagnosed at autopsy, classify as 
dead at TB diagnosis 
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Comment:  
If a person dies while taking isoniazid as preventive therapy for latent TB infection, and this person is 
found after death to have had TB disease, he/she should be classified as Dead at TB diagnosis. 
If you selected Dead at TB diagnosis, enter date of death. 
Description Comment 
Date of death 
(e.g., 01/17/2005) 
Month, day, and year patient 
died 
If day is unknown, enter 99 as the default value 
(e.g., 01/99/2005). 





(related to TB 
disease) 
TB was 
· The immediate cause 
or 
· An underlying cause 
or  
· Another significant condition 
contributing to death (even if 
TB was not the main cause 
of death) 
Written documentation of the cause of death 
(e.g., death certificate, autopsy report, medical 
record) is recommended. However, oral 
information from a reliable source (e.g., a health 
care provider) will be accepted. 
 
A death certificate is not necessarily required to 
complete this field. In some cases deaths may be 
certified before receipt of results of  
· Positive M. tuberculosis culture 
or 
· Other findings consistent with TB  
If the patient died as a result of a surgical 
procedure that was indicated for TB, or TB 
complicated a surgical procedure not related to 
TB. 
No 
(unrelated to TB 
disease) 
TB was not  
· The immediate cause 
or 
· An underlying cause 
or  
· Another significant condition 
contributing to death 
Unknown Cause of death is not known. Every effort should be made to determine if 
death was related to TB disease before 
classifying as unknown. 
Note: This should reflect current or active TB disease (not LTBI) whenever death certificate or death 
documentation is used. 
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16. Site of TB Disease  
 
Primary Purpose: Surveillance. Data are used to document site of TB disease. 
Option 
(select all that apply) 
Description Comment 
Pulmonary, pleural, 
lymphatic, etc.  
Select boxes corresponding to the 
site(s) of TB disease. 
Other: enter  
anatomic code(s) 
If site of TB disease is a site 
other than those listed, enter the 
anatomic code(s) (see  
Appendix C – Anatomic Codes). 
You may enter as many as 3 
Other anatomic codes. 
Refer to the listings for site of TB 
disease and anatomic codes. In 
Appendix C – Anatomic Codes, 
anatomic codes for Other are marked 
with an asterisk (*). Select only from 
sites marked with an asterisk (*). 
Anatomic codes without an asterisk 
are parts of organ systems 
corresponding to Site of TB Disease. 
Site not stated If you selected Site not stated, do not 
check any other box. 
 
Note: For the purposes of the RVCT training materials, use the codes listed in the appendices. Some 
software programs used to enter data on the RVCT may NOT use the codes listed in the appendices. 
For example, the Anatomic Codes may be a drop-down item where you choose the actual site rather 
than enter a code. For more information, see instructions for the software you use. 
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Comment: If more than 1 organ or disease site is involved 
If there is evidence that more than 1 organ or disease site is involved, check all involved sites of disease. 
Comment: Lymphatic intrathoracic 
Lymphatic intrathoracic includes hilar, bronchial, mediastinal, peritracheal, and other lymph nodes within 
the thorax. 
Comment: Miliary TB 
Unlike the previous RVCT form, the new form has no place to select miliary TB in Site of Disease (item 
16). If the report of the initial chest radiograph or the initial chest CT scan indicates “miliary TB or a 
miliary or bilateral micronodular pattern,” record this finding under Initial Chest Radiograph (item 
22A) or Initial Chest CT Scan or Other Chest Imaging Study (item 22B), respectively. However, 
pulmonary should be selected as Site of Disease (item 16) if the chest x-ray or CT scan shows evidence 
of nodules consistent with miliary TB. 
Miliary TB is a serious type of tuberculosis infection. It is a clinical or radiologic finding, rather than a  
site of disease. Miliary TB is the result of a TB lung infection eroding into the bloodstream and from there 
disseminating throughout the body to multiple organs. It appears on radiograph as a great number of small 
(1- to 2-mm), well-defined nodules that look like millet seeds scattered throughout the lungs, hence the 
name “miliary.”  
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RVCT 
(page 2 of 3) 
Items 17 – 25 
Page 2 of the RVCT report includes instructions for completing items 17 – 25. It includes data about 
laboratory results and primary reason the patient was evaluated for TB disease.   
 
 57 




Primary Purpose: Case management and surveillance. This result is one factor in determining whether 




Positive The result of any sputum examination was 
positive for acid-fast bacilli (AFB). 
Negative Results of all examinations were negative. 
Not done Sputum smear examination is known not to have 
been done. 
Unknown It is not known whether a sputum smear 
examination was performed. 
          or 
Results are not known for a reason other than 
pending results (e.g., result was lost or specimen 
was contaminated, and no other specimen can be 
obtained). 
If an initial sputum specimen 
was collected and results are 
unknown, but results later 
become known, update the 
results. 
 
Comments: Sputum  
Sputum includes spontaneous and induced sputum. Do not include the results of microscopic examination 
of pulmonary secretions obtained by tracheal suction, bronchoscopy procedures (e.g., bronchial washing 
or lavage, scrapings, biopsies), or gastric aspiration. See Smear/Pathology/Cytology of Tissue and 
Other Body Fluids (item 19). 
Sputum should have been collected during the diagnostic evaluation or shortly thereafter. Do not record 
specimens collected after the patient has received treatment for more than 2 weeks. 
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Month, day, and year the first 
sputum specimen with a positive 
result was collected (e.g., 
01/17/2009) 
If several sputum examinations were done and 
the results of 1 or more sputum examinations 
were positive, enter the date the first sputum 
specimen with a positive result was collected. 
Month, day, and year the first 
negative sputum specimen was 
collected (e.g., 01/17/2009) if all 
results were negative 
If several sputum examinations were done and 
all results were negative, enter the date the first 
sputum specimen with a negative result was 
collected. 
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Primary Purpose: Case management and surveillance. This result is a main factor in determining 





Positive The result of any (or the only) sputum  
culture was positive for M. tuberculosis 
complex. 
                                                                                                  
Negative 
Results of all sputum cultures were
negative for M. tuberculosis complex. 
Not done It is known that the sputum culture was not  
done. 
Unknown It is not known whether a sputum culture 
was performed. 
          or 
Results are not known for a reason other 
than pending results (e.g., result was lost  
or specimen was contaminated, and no other 
specimen can be obtained). 
If an initial sputum specimen was 
collected and results are unknown, 
but results later become known, 
update the results. 
Comment: Sputum 
Sputum includes spontaneous and induced sputum. Do not include the culture results of pulmonary 
secretions obtained by tracheal suction, bronchoscopy procedures (e.g., bronchial washing or lavage, 
scrapings, biopsies), or gastric aspiration. For more information, see Culture of Tissue and Other Body 
Fluids (item 20). 
Sputum should have been collected during diagnostic work-up or shortly thereafter. Do not record 
specimens collected after the patient has received treatment more than 2 weeks. 
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Month, day, and year the first sputum 
specimen with a positive culture result was 
collected (e.g., 01/17/2009) 
If several sputum cultures were 
performed and the results of 1 or 
more were positive for M. 
tuberculosis complex, enter the date 
the first sputum culture with a positive 
result was collected. 
Month, day, and year the first sputum 
specimen with a negative culture result was 
collected (e.g., 01/17/2009) if all results were 
negative 
If several sputum cultures were done 
and all results were negative, enter 
the date the first sputum specimen 
with a negative result was collected.  





Month, day, and year the 
laboratory reported the result 
(e.g., 01/17/2009) 
This date can be found on the laboratory report 
as the date the report is released or made  
available. 
 
If the day is unknown, enter 99 as the default 
value (e.g., 01/99/2009). 






Any laboratory associated with a 
local or a state health department 
Commercial 
laboratory 
Any laboratory that charges  
a fee for each specimen  
processed or test performed 
Other Any other laboratory that is  
not considered a public health 
laboratory or a commercial 
laboratory 
Hospital laboratories (e.g., National Jewish 
Health hospital laboratory) or laboratories 
associated with federal public health agencies 
(e.g., Centers for Disease Control and 
Prevention, Veterans Administration, Indian 
Health Service [IHS], Tribal Health 
Department, or Bureau of Prisons) 
National Jewish Health hospital laboratory 
sometimes charges for services, but for the 
purposes of the RVCT it is categorized as 
“Other.” 
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Primary Purpose: Case management and surveillance. This result is a factor in determining whether 
the patient’s disease meets the public health definition of TB.  
Note: This item is for recording results of a smear, or pathology, or cytology of tissue and/or other 
body fluids. In this item, “tissue and other body fluids” does not include sputum. Examples of tissue 
and other body fluids are tracheal aspirate, bronchial cells and fluid, urine, bone marrow, lymph node, 
cerebral spinal fluid, lung tissue or fluid, and pleural fluid that are collected from various procedures 
(e.g., bronchoscopy, bronchial washing or lavage, biopsy, gastric aspiration, pleural aspiration).  
 
Results from sputum smear examinations and sputum cultures should be entered under Sputum Smear 




Positive Any tissue or body fluid other than sputum that (see 
Note above)  
· Tested positive by smear examination  
          or 
· Showed granulomas, granulomatous inflammation, 
or other pathologic or histologic findings consistent 
with TB disease during a pathologic/cytologic 
examination. (Such findings are listed on the 
pathology or the cytology report.) 
Any positive result 
supersedes a negative 
result. 
Negative All specimens of tissue or fluid that  
· Tested negative by smear examination  
          or  
· Showed no evidence of granulomas, granulomatous 
inflammation, or other pathologic or histologic 
findings consistent with TB disease during a 
pathologic/cytologic examination. (Such findings 
are listed on the pathology or the cytology report.) 
Not done Examinations of tissue or fluids are known not to have 
been done. 
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Unknown It is not known whether tissue or fluids  
· Were examined 
          or 
· Results are not known for a reason other than 
pending results (e.g., result was lost or specimen 
was contaminated, and no other specimen can be 
obtained). 
If an initial specimen was 
collected and results are 
unknown, but results later 
become known, update 
the results. 
Comment: When to collect specimen  
A smear, or pathology, or cytology specimen should have been collected during diagnostic workup or 
shortly thereafter. Do not record specimens collected after the patient has received treatment more than 2 
weeks. 
For positive or negative results of an examination for a smear or, pathology, or cytology of tissue and/or 




Month, day, and year the first  
specimen with a positive result was 
collected (e.g., 01/17/2009) 
If several specimen (tissue or fluid) 
examinations were done and the results of 1 
or more examinations were positive, enter the 
date the first specimen with a positive result 
was collected. 
Month, day, and year the first negative 
specimen was collected (e.g., 
01/17/2009) if all results were negative 
If several specimen examinations were done 
and all results were negative, enter the date 




Enter appropriate anatomic code (e.g., 
30 for pericardium) from  Appendix 
C – Anatomic Codes. 
Note: For the purposes of the RVCT training materials, use the codes listed in the appendices. Some 
software programs used to enter data on the RVCT may NOT use the codes listed in the appendices. 
For example, the Anatomic Codes may be a drop-down item where you choose the actual site rather 
than enter a code. For more information, see instructions for the software you use. 
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For Type of Exam, select both of the following if applicable. 
Option 
(select all that apply) 
Comment 
Smear Select the type(s) of exam that correspond(s) to the result selected in 
item 19. 
Pathology/cytology 
Comment: Any positive result supersedes a negative result in reporting TB diagnostic criteria.   
If the results are discrepant (smear negative, pathology positive), then Type of Exam should correspond to 
the result captured as positive.  If both smear and pathology had been positive, both smear and 
pathology/cytology should be checked under Type of Exam. Likewise, if both smear and pathology had 
been negative, then both smear and pathology/cytology should be checked under Type of Exam.  
 
Example: Positive result superseding a negative result 
If the smear results were negative and the pathology was positive, then Type of Exam selected should be 
Pathology.  In this case, smear would not be selected because the result was negative.  
                   
Reporting TB Diagnostic Criteria 











1st Test 2nd Test 
Negative Diagnosis 
(All TB Test Results Are Negative) 
Negative Negative 
1st Test 2nd Test 
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Primary Purpose: Case management and surveillance. This result is a factor in determining whether 
the patient’s disease meets the public health definition of TB.  
Note: The term “tissue and other body fluids” does not include sputum. Examples of tissue and other 
body fluids are tracheal aspirate, bronchial cells and fluid, urine, bone marrow, lymph node, cerebral 
spinal fluid, lung tissue or fluid, and pleural fluid collected from various procedures (e.g., 
bronchoscopy, bronchial washing or lavage, biopsy, gastric aspiration, pleural aspiration).  
Results from sputum smear examinations and sputum cultures should be entered under Sputum Smear 




Positive The culture results for any tissue or fluid culture 
other than sputum (see Note above) was positive 
for M. tuberculosis complex.  
If an initial specimen was 
collected and results are 
unknown, but results later 
become known, update the 
results. 
 
Any positive result supersedes 
a negative result. 
Negative The culture results for all tissue or fluid cultures, 
other than sputum cultures, were negative for M. 
tuberculosis complex. 
 
Not done It is known that tissue or fluid cultures were not 
done. 
Unknown It is not known whether tissue or fluid cultures 
were performed 
          or 
Results are not known for a reason other than 
pending results (e.g., result was lost or specimen 
was contaminated, and no other specimen can be 
obtained). 
If an initial specimen was 
collected and results are 
unknown, but results later 
become known, update the 
results. 
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Comment:  When to collect specimen 
Specimens of tissue and other body fluids should have been collected during diagnostic workup or shortly 
thereafter. Do not record specimens collected after the patient has received treatment for more  
than 2 weeks. 
 




Month, day, and year the first  
specimen with a positive result 
was collected (e.g., 
01/17/2009) 
If cultures were performed on several specimens 
of tissue or fluid and the results of 1 or more were 
positive for M. tuberculosis complex, enter the 
date the first specimen with a positive culture 
result was collected. 
Month, day, and year the first  
specimen with a negative result 
was collected (e.g., 1/17/2009) 
if all results were negative 
If several cultures were done and all results were 
negative, enter the date the first specimen with a 
negative result was collected.  
Anatomic code Enter appropriate anatomic 
code (e.g., 30 for pericardium) 
from Appendix C – Anatomic 
Codes. 
Note: For the purposes of the RVCT training materials, use the codes listed in the appendices. Some 
software programs used to enter data on the RVCT may NOT use the codes listed in the appendices. 
For example, the Anatomic Codes may be a drop-down item where you choose the actual site rather 
than enter a code. For more information, see instructions for the software you use. 
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Month, day, and year the result 
was reported by the laboratory  
(e.g., 01/17/2009) 
This date can be found on the laboratory report as 
the date the report is released or made available. 
If the day is unknown, enter 99 as the  
default value (e.g., 01/99/2009). 






Any laboratory associated with 




Any laboratory that charges  
a fee for each specimen  
processed or test performed 
Other Any other laboratory that is  
not considered a public health 
laboratory or a commercial 
laboratory 
Hospital laboratories (e.g., National Jewish Health 
hospital laboratory) and laboratories associated 
with federal public health agencies (e.g., Centers 
for Disease Control and Prevention, Veterans 
Administration, Indian Health Service [IHS], 
Tribal Health Department, and Bureau of Prisons) 
National Jewish Health hospital laboratory 
sometimes charges for services, but for the 
purposes of the RVCT it is categorized as 
“Other.” 
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Primary Purpose: Case management and surveillance. This result is a factor in determining whether 




Positive Any NAA test result was positive for M. 
tuberculosis complex. 
Any positive result supersedes 
all other test results (e.g., 1 
positive and 2 negatives = 
positive; 1 indeterminate and 1 
negative and 1 positive = 
positive).  
Negative No NAA test results were positive for M. 
tuberculosis complex and at least one result was 
negative. 
A negative result supersedes 
indeterminate (e.g., 1 negative 
and 1 indeterminate = 
negative). 
Not done NAA test was not performed. 
Unknown It is not known whether an NAA test was 
performed. 
          or 
NAA test results are not known or result is not 
known for a reason other than pending results. 
If an initial specimen was 
collected and results are 
unknown, but results later 
become known, update the 
results. 
Indeterminate All NAA tests were indeterminate (e.g., 
inconclusive, inhibitory). 
All tests are indeterminate. 
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Month, day, and year the 
first sputum specimen with 
a positive result was 
collected (e.g., 01/17/2009) 
If several specimens were collected and the NAA 
test results of 1 or more were positive for M. 
tuberculosis complex, enter the date the first 
specimen with a positive result was collected. 
Month, day, and year the 
first sputum specimen with 
a negative result was 
collected (e.g., 01/17/2009) 
if all results were negative 
If several specimens were collected and all NAA 
test results were negative, enter the date the first 
sputum specimen with a negative result was 
collected.  





Not sputum Enter appropriate anatomic code (e.g., 30 
for pericardium) from Appendix C – 
Anatomic Codes  
Note: For the purposes of the RVCT training materials, use the codes listed in the appendices. Some 
software programs used to enter data on the RVCT may NOT use the codes listed in the appendices. 
For example, the Anatomic Codes may be a drop-down item where you choose the actual site rather 
than enter a code. For more information, see instructions for the software you use. 
 





Month, day, and year the result was 
reported by the laboratory (e.g., 
01/17/2009) 
This date can be found on the 
laboratory report as the date the report 
is released or made available. 
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Any laboratory associated with a local or 
a state health department 
Commercial 
laboratory 
Any laboratory that charges  
a fee for each specimen  
processed or test performed 
Other Any other laboratory that is  
not considered a public health 
laboratory or a commercial laboratory 
Hospital laboratories (e.g., National 
Jewish Health hospital laboratory) 
and laboratories associated with 
federal public health agencies (e.g., 
Centers for Disease Control and 
Prevention, Veterans Administration, 
Indian Health Service [IHS], Tribal 
Health Department, and Bureau of 
Prisons) 
Comment: Nucleic Acid Amplification Tests 
The MMWR report, “Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the 
Diagnosis of Tuberculosis,” provides information on the NAA tests that have been approved by the Food 
and Drug Administration for use with AFB smear-positive respiratory specimens. Accessible at 
www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm.
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Primary Purpose: Case management and surveillance. This is part of a diagnostic evaluation used to 
determine whether the patient’s disease meets the public health definition of TB. 




Normal Initial chest radiograph(s) showed no abnormalities consistent with TB. This 
category includes any other abnormalities that are not consistent with TB.  
Abnormal 
(consistent with TB) 
Any initial chest radiograph showing abnormalities (e.g., hilar adenopathy, 
effusion, infiltrate[s], cavity, scarring) consistent with TB. 
Not done It is known that the initial chest radiograph was not done. 
Unknown It is not known whether an initial chest radiograph was done. 
          or 
Result of initial chest radiograph is not known or result is not known for a 
reason other than pending results. 
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Yes Any initial chest radiograph(s) showed evidence of miliary disease 




Comment: Miliary TB 
Unlike the previous RVCT form, the new form has no place to select miliary TB in Site of Disease (item 
16). If the report of the initial chest radiograph or the initial chest CT scan indicates “miliary TB or a 
miliary or bilateral micronodular pattern,” record this finding under Initial Chest Radiograph (item 
22A) or Initial Chest CT Scan or Other Chest Imaging Study (item 22B), respectively. However, 
pulmonary should be selected as Site of Disease (item 16) if the chest x-ray or CT scan shows evidence 
of nodules consistent with miliary TB. 
Miliary TB is a serious type of tuberculosis infection. It is a clinical or radiologic finding, rather than a  
site of disease. Miliary TB is the result of a TB lung infection eroding into the bloodstream and from there 
disseminating throughout the body to multiple organs. It appears on radiograph as a great number of small 
(1- to 2-mm), well-defined nodules that look like millet seeds scattered throughout the lungs, hence the 
name “miliary.”  
 72 




Primary Purpose: Case management. This is part of a diagnostic evaluation used to determine whether 
the patient’s disease meets the public health definition of TB. 
Select the result of the initial chest computerized tomography (CT) or other chest imaging study such as 





Normal Initial chest CT scan or other chest imaging study showed no abnormalities  
consistent with TB. This category includes any other abnormalities that are not 




Any initial chest CT scan or other chest imaging study showed abnormality  
(e.g., hilar adenopathy, effusion, infiltrate[s], cavity, scarring) consistent with TB. 
Not done It is known that the initial chest CT scan or other chest imaging study was not done. 
Unknown It is not known whether an initial chest CT scan or other chest imaging study was 
done. 
          or 
Result of initial chest CT scan or other chest imaging study is not known or result is 
not known for a reason other than pending results. 
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Evidence of a 
cavity 
Yes Any initial chest CT scan or other chest imaging study showed  








Yes Any initial chest CT scan or other chest imaging study showed  
evidence of miliary disease (e.g., miliary TB, or miliary or 




Comment: Miliary TB 
Unlike the previous RVCT form, the new form has no place to select miliary TB in Site of Disease (item 
16). If the report of the initial chest radiograph or the initial chest CT scan indicates “miliary TB or a 
miliary or bilateral micronodular pattern,” record this finding under Initial Chest Radiograph (item 
22A) or Initial Chest CT Scan or Other Chest Imaging Study (item 22B), respectively. However, 
pulmonary should be selected as Site of Disease (item 16) if the chest x-ray or CT scan shows evidence 
of nodules consistent with miliary TB. 
Miliary TB is a serious type of tuberculosis infection. It is a clinical or radiologic finding, rather than a  
site of disease. Miliary TB is the result of a TB lung infection eroding into the bloodstream and from there 
disseminating throughout the body to multiple organs. It appears on radiograph as a great number of small 
(1- to 2-mm), well-defined nodules that look like millet seeds scattered throughout the lungs, hence the 
name “miliary.”  
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23. Tuberculin (Mantoux) Skin Test at Diagnosis 
 
Primary Purpose: Case management. This result helps guide clinicians in diagnosing TB infection and 
is a factor in determining whether the patient’s disease meets the public health definition of TB. 
 
Positive or negative result of the tuberculin skin test (TST) should be interpreted according to Table 7 of 
the currently accepted guidelines (www.cdc.gov/mmwr/PDF/rr/rr4906.pdf).
Guidelines for Entering TST Results 
Enter Do Not Enter 
Results from a TST performed during the current 
diagnostic evaluation 
A patient’s undocumented self-report of a 
previous positive result is not acceptable 
May enter previous positive test result 
· If patient had tested positive to a previous TST  
and  
· The previous positive result is documented in 
the medical record.  
A previous negative TST result (reported by the 





Positive Meets the criteria for a positive TST result.  
Negative Result of TST did not meet current criteria for a positive test result.  
Not done TST was not performed 
          or 
Patient reports a positive result of an earlier TST, but it cannot be documented,  
and now the patient refuses a TST. 
 
Unknown It is not known whether a TST was performed  
          or  
result is not known for a reason other than pending results. 
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For positive or negative TST results, enter the following information.
Description Comment 
Date TST placed Month, day, and year the TST was 
placed (e.g., 01/17/2009) 
If the month or day is unknown, enter 
99 as the default value (e.g., 
01/99/2009). 
 
Year must be recorded. Do not use 
9999 for the year.  
Millimeters (mm) 
of induration 
Measurement (in millimeters, mm) of 
the induration (e.g., 05 mm) 
If the millimeters of the induration are 
not expressed, enter 99 as the default 
value. 
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5 or more millimeters 10 or more millimeters 15 or more millimeters 
An induration of 5 or more 
millimeters is considered 
positive for 
· People living with HIV  
· Recent contacts of persons 
with infectious TB 
· People who have previously 
had TB disease  
· Patients with organ 
transplants and other 
immunosuppressed patients 
(including patients taking a 
prolonged course of oral or 
intravenous corticosteriods 
or TNF-a antagonists) 
An induration of 10 or more 
millimeters is considered positive 
for 
· People who have come to the 
U.S. within the last 5 years 
from areas of the world where 
TB is common (for example, 
Asia, Africa, Eastern Europe, 
Russia, or Latin America) 
· People who inject illegal drugs  
· Mycobacteriology lab workers 
· People who live or work in 
high-risk congregate settings 
· People with certain medical 
conditions that place them at 
high risk for TB (silicosis, 
diabetes mellitus, severe kidney 
disease, certain types of cancer, 
and certain intestinal 
conditions)  
· Children younger than 4 years  
· Infants, children, and 
adolescents exposed to adults in 
high-risk categories 
An induration of 15 or more 
millimeters is considered 
positive for 
· People with no known 
risk factors for TB 
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24. Interferon Gamma Release Assay for Mycobacterium 
tuberculosis at Diagnosis 
 
Primary Purpose: Case management. This result helps guide clinicians in diagnosing TB infection and 
is a factor in determining whether the patient’s disease meets the public health definition of TB. 
Interferon gamma release assays (IGRAs) are blood tests for detecting M. tuberculosis infection.  




Positive Any IGRA result was interpreted as “M. 
tuberculosis infection is likely.” 
Any positive result supersedes 
all other test results (e.g., 1 
positive and 2 negatives = 
positive; 1 indeterminate and 1 
negative and 1 positive = 
positive).  
Negative All IGRA results were interpreted as “M. 
tuberculosis infection is unlikely.” 
A negative result supersedes 
indeterminate (e.g., 1 negative 
and 1 indeterminate = negative). 
Not done IGRA was not performed. 
Unknown It is not known whether IGRA was 
performed. 
          or 
IGRA results are not known, or result is not 
known for a reason other than pending results. 
Indeterminate IGRA results could not be determined to be 
positive or negative. 
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For positive or negative results of IGRA, enter the following information.
Description Comment 
Date collected Month, day, and year the 
blood sample was collected 
(e.g., 01/17/2009)  
If several blood tests were performed and the 
results of one or more tests were positive for M. 
tuberculosis complex, enter the date the first blood 
test with a positive result was collected. 
Test type 
(specify) 
Specify the blood test  
performed [e.g., 
QuantiFERON®-TB Gold test 
(QFT-G)] 
If more than 1 test was performed, enter the name 
of the test used for the specimen for which you 
entered the result. 
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25. Primary Reason Evaluated for TB Disease  
 
 
Primary Purpose: Programmatic function. Data are helpful in assessing how a TB case was found.  
Select the single primary or initial reason the patient was evaluated for TB disease. The definition of 
“primary or initial reason” is the situation or reason that led to the initial suspicion that the patient might 
have TB disease. If the patient was referred for evaluation, but the reason for the evaluation is unknown, 




TB symptoms Signs and symptoms consistent with TB 
(e.g., prolonged persistent cough, fever, 
lymphadenopathy, night sweats, weight 
loss) 
Select if patient seeks medical attention 
because of symptoms. Do not select if 




Incidental chest radiograph consistent 
with TB disease 
Reason for the chest radiograph should 
be independent of the other choices 
listed and should not have been the 
result of suspicion of TB disease. 
Contact 
investigation 
Result of a contact investigation or 
source case finding 
Targeted testing Positive result of tuberculin skin test 
(TST) or interferon gamma release 
assay (IGRA) administered because the 
patient was specifically considered as 
high risk for TB (e.g., persons from area 
of the world with high rate of TB) or as 
part of a testing program focused on 
specific groups at risk for TB 
Do not select if another reason (e.g., 
contact investigation, immigration 
medical examination, employment/ 
administrative testing, or health care  
worker status) is more appropriate  




Positive result of TST or IGRA 
administered because the patient was a 
health care worker 
Refers to all paid and unpaid persons 
working in health care settings who 
have the potential for exposure to M. 
tuberculosis. 
For health care workers being evaluated 
for TB disease, health care worker 
supersedes targeted testing and 
employment/administrative testing. 
Other situations (e.g., TB symptoms, 
contact investigation) supersede health 




Results from routine physical 
examination before or periodically 
during employment, TST or IGRA 
required by employer, or primary or 
secondary school program for routine 
TST 
Reflects an administrative requirement 
(e.g., a TST program applied to all 5th 
graders in a school or to all job 
applicants) rather than testing of a group 
considered at high risk. If TST or IGRA 
was performed because the person was 
considered at high risk, select targeted 
testing or a more appropriate category, 
such as health care worker. If 
employment was health care–related, 




Findings of a medical examination that 
was part of the immigration application 
process 
A medical examination is mandatory for 
specific categories of persons seeking 
admission to the United States (e.g., 
immigrants, refugees, asylees). These 
medical examinations may be 
performed overseas or in the United 
States depending on the situation. In 
addition, a medical examination may be 
required for some persons applying for 
nonimmigrant visas or special status 
(e.g., parolees) for temporary admission 
to the United States. 
Incidental lab 
result  
The clinical evaluation was for 
something other than TB (e.g., 
bronchoscopy or autopsy). Specimens 
were collected and submitted for 
evaluation of TB and other diseases for 
diagnostic completeness. TB was not 
expected.   
Unknown  Reason for evaluating the patient not 
known 
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Example: TB Symptoms  
If a TB patient seeks medical care because of TB symptoms, select TB Symptoms as the primary  
reason for the evaluation. If, however, a TB patient was initially encountered via a contact investigation 
and during that investigation was also noted to have TB symptoms, select Contact Investigation as the 
primary reason for the evaluation. 
Example: Abnormal Chest Radiograph  
If the chest radiograph was performed during a workup for TB disease because of a positive TST result 
obtained during targeted testing, select Targeted Testing. However, if a chest radiograph was  
performed as part of preoperative testing (TB disease was not suspected), select Abnormal Chest  
Radiograph. 
Examples: Health Care Worker 
Includes full time, part-time, temporary, or contract staff. Examples include:  
· Physicians 
· Nurses 
· Health aides 
· Dental workers 
· Health technicians 
· Staff in laboratories and morgues 
· Emergency medical personnel 
· Students enrolled in health care 
programs 
· Persons who deliver health care in the community 
(e.g., public health nurse, visiting nurse, outreach 
worker) 
· Persons not involved directly in patient care, but 
potentially at risk for occupational exposure  
(e.g., correctional facility staff, volunteers; outreach 
workers; dietary/nutritional, housekeeping, 
maintenance, clerical, janitorial staff, administrative 
staff and supervisors) 
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 RVCT  
(page 3 of 3) 
Items 26 – 37 
 
Page 3 of the RVCT report provides instructions for completing items 26 – 37. It includes data about risks 
associated with TB, the date that therapy was started, and the initial drug regimen. 
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Primary Purpose: Case management and surveillance. Data are used to determine TB/HIV co-
morbidity. 
Note: CDC recommends that all persons receive HIV testing at the time of TB diagnostic evaluation or 
TB diagnosis. Refer to the CDC public health surveillance definition of HIV infection 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a2.htm). 
Note: Documentation of an HIV test result is needed. This documentation from a hospital, clinic, or 
private provider, should be written evidence of the test result, or it can be notes in the medical record. 





Negative Documented negative result of HIV test at the time of 
TB diagnostic evaluation or at TB diagnosis or earlier, 
but not exceeding 1 year 
Undocumented report is 
not acceptable. 
Positive  Laboratory result interpreted as positive according to 
published criteria 
          or   
Documented positive result of an earlier HIV test or 
documented earlier diagnosis of HIV infection or AIDS 
Undocumented report is 
not acceptable. 
Indeterminate Documented indeterminate result of an HIV test at the 
time of TB diagnostic evaluation or TB diagnosis 
Undocumented report is 
not acceptable. 
Refused HIV testing offered but declined at the time of the TB 
diagnostic evaluation or TB diagnosis 
Not offered HIV testing not offered at the time of the TB diagnostic 




HIV test performed at the time of the TB diagnostic 
evaluation or TB diagnosis, but the results not known to 
the TB program, or result is not known for a reason 
other than pending results. 
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Unknown Not known whether the patient  
· Has had an HIV test 
· Was ever offered a test 
· Was referred for HIV counseling and testing (e.g. 
anonymous testing center, private testing center) 
Comments: Negative HIV status 
· Undocumented patient report that an HIV test result was negative is not acceptable. Such patients 
should be offered the opportunity to be tested for HIV. 
· If a patient has had a negative test result, regardless of when the HIV test was performed, the 
patient should be offered HIV testing at the time of TB diagnostic evaluation or TB diagnosis. 
· If the patient had received HIV testing less than 1 year before the TB diagnostic evaluation or 
TB diagnosis, the documented results were negative for HIV infection, and the patient reports no 
risk factor for HIV, check Negative for this item. 
· A documented negative HIV test from 1 year ago or longer is not valid for checking Negative. 
Note: Update this item if additional information is obtained during the course of treatment. 
 
For Positive HIV status at the time of TB diagnosis, enter the following information. 
Description 
State HIV/AIDS  
patient number 
Can be obtained from the state or local HIV/AIDS surveillance program 
City/county HIV/AIDS  
patient number 
Can be obtained from the state or local HIV/AIDS surveillance program 
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27. Homeless Within Past Year  
 
Primary Purpose: Surveillance. Data are used to determine the extent to which recent homelessness is 




No Not homeless during the 12 months before the TB diagnostic evaluation was 
performed or initiated 
Yes Homeless at any time during the 12 months before the TB diagnostic  
evaluation was performed or initiated 
Unknown Not known whether the patient was homeless during the 12 months  
before the TB diagnostic evaluation was performed or initiated 
Comments: Definitions for Homeless 
There are many definitions for homeless (National Coalition for the Homeless).  A homeless  
person may be an individual who has 
1. No fixed, regular, and adequate nighttime residence  
and 
2. A primary nighttime residence that is 
a. A supervised publicly or privately operated shelter designed to provide temporary living  
accommodations, including welfare hotels, congregate shelters, and transitional housing for 
the mentally ill  
or 
b. An institution that provides a temporary residence for individuals intended to be  
institutionalized 
or 
c. A public or private place not designated for, or ordinarily used as, a regular sleeping  
accommodation for human beings. 
 
A homeless person may also be defined as a person who has no home (e.g., is not paying rent, does not 
own a home, and is not steadily living with relatives or friends). Persons in unstable housing situations 
(e.g., alternating between multiple residences for short stays of uncertain duration) may also be 
considered homeless.  
 
 86 
A homeless person may be a person who lacks customary and regular access to a conventional dwelling 
or residence. Included as homeless are persons who live on streets or in nonresidential buildings. Also 
included are residents of homeless shelters and shelters for battered women. Residents of welfare hotels  
and single room occupancy (SRO) hotels could also be considered homeless. In the rural setting, where 
there are usually few shelters, a homeless person may live in non-residential structures, or substandard 
housing, or with relatives. Homeless does not refer to a person who is imprisoned or in a correctional 
facility.  
Note: The homeless category is limited to living conditions in the United States and does not apply to 
living in refugee camps outside the United States. 
Note: Update this item if additional information is obtained during the course of treatment. 
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28. Resident of Correctional Facility at Time of Diagnosis   
 
Primary Purpose: Surveillance. Data are used to determine if residence in a correctional facility is 
associated with TB disease. 
Note: Direct the questions regarding classification of a specific correctional facility (federal, state,  




No Not an inmate when the TB diagnostic evaluation was performed or initiated 
Yes An inmate of a correctional facility when the TB diagnostic evaluation was 
performed or initiated 
Unknown Not known whether the patient was an inmate when the TB diagnostic evaluation 
was performed or initiated 
 
If you selected Yes, indicate the type of correctional facility where the patient was an inmate. If the TB 
patient was a resident of more than 1 facility during the diagnostic evaluation, select the facility where the 




Federal prison Confinement facility administered by a federal agency; includes privately operated 
federal correctional facilities 
State prison Confinement facility administered by a state agency; includes privately  
operated state correctional facilities 
Local jail Confinement facility usually administered by a local law enforcement agency, 
intended for adults but sometimes also containing juveniles; holds persons 
detained pending adjudication and/or persons committed after adjudication, 




Public or private residential facility; includes juvenile detention centers, reception 
and diagnostic centers, ranches, camps, farms, boot camps, residential treatment 





Includes Immigration and Customs Enforcement (ICE) detention centers, Indian 
reservation facilities (e.g., tribal jails), military stockades and jails, federal park 
police facilities, police lockups (temporary holding facilities for persons who have 
not been formally charged in court), or other correctional facilities that are not 
included in the other specific choices 
Unknown Inmate when the TB diagnostic evaluation was performed, but the type of 
correctional facility is not known 
Comment: Correctional facility at time of diagnosis  
If a patient is an inmate at a correctional facility and goes to a hospital for TB diagnostic evaluation, you 
would select  
· Yes, an inmate of a correctional facility when the TB diagnostic evaluation was performed
· The type of correctional facility (rather than the hospital) where he/she resided at time of 
diagnostic evaluation  
Comment: Local Jail  
Excludes temporary holding facilities, or lockups, that do not hold persons after they have been formally 
charged in court. Includes city and county jails and privately operated local correctional facilities. Report 
federal and state prisoners who are boarded at local jails as residents of the local jail. 
Comment: Juvenile Correctional Facility  
Includes juveniles charged or adjudicated as delinquents, juveniles who are not delinquents or criminal 
offenders (e.g., runaways, truants, incorrigibles, curfew violators), and juveniles committed or detained 
for treatment of abuse, dependency, neglect, or other reasons. Report juveniles who are boarded at federal 
or state prisons or local jails as residents of the facility at which they are boarded. 
 





No Response indicates whether the patient was under the custody of ICE at the 
time of diagnosis. Persons in ICE custody can be housed in standalone ICE 
detention centers, or other correctional facilities (e.g., federal or state prison, 
local jail) when a standalone ICE detention center is not available. 
Yes 
 
Note: Update this item if additional information is obtained during the course of treatment. 
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Primary Purpose: Surveillance. Data are used to determine if residence in a long-term care facility is 
associated with TB disease. 
Note: The state licensing agency for long-term care facilities can assist in determining the  




No Not a resident of a long-term care facility when the TB diagnostic evaluation was 
performed 
Yes Resident of a long-term care facility when the TB diagnostic evaluation was performed 
Unknown  Not known whether the patient was a resident of a long-term care facility when the 
TB diagnostic evaluation was performed 
If you selected Yes, indicate the type of long-term care facility of which the patient was a resident. If the 
TB patient was a resident of more than 1 facility during the diagnostic evaluation, select the facility where 




Nursing home Freestanding facility with 3 or more beds 
(i.e., is classified as a residential facility 
or congregate residential setting) that 
provides nursing care services (e.g., 
nursing or medical care and/or 
supervision of medications that may be 
self-administered) 
Facilities may be certified by Medicare 
or Medicaid or may be licensed by the 
state as a nursing home (e.g., skilled 
nursing facility, intermediate care 




Distinct unit with 3 or more beds that is 
physically attached to, or managed by, a 
hospital 
Facilities may be certified by Medicare 





Facility with 3 or more beds (i.e., is 
classified as a residential facility or 
congregate residential setting) and meets both 
of the following criteria:  
1. Not classified as a nursing home or 
hospital-based facility, as described above 
and  
 
2. Provides personal care or supervision (not 
nursing care services) to its residents, in 
addition to room and board (e.g., help with 
bathing, dressing, eating, walking, shopping) 
This might be an assisted living facility. 
Mental health  
residential 
facility 
Facility that provides 24-hour care in a 
hospital, residential treatment, or 
supportive setting 
Include state and local mental hospitals, 
private psychiatric hospitals, general 
hospitals, the Department of Veterans 
Affairs (VA), residential treatment 
centers for emotionally disturbed 
children, and multiservice mental health 
organizations with residential treatment 
programs. 
For other federal mental health 
residential facilities, select “Other 
long-term care facility.” Examples 
include the Department of Defense, 
Bureau of Prisons, Public Health 
Service, Indian Health Service, and 






Only long-term rehabilitation or 
residential facilities designated for 
treatment of 30 days or longer 
Exclude all ambulatory or outpatient 
facilities, detoxification units, and 
facilities designated for fewer than 30 
days of treatment. The state agency 
responsible for alcohol and drug treatment 
can assist in determining whether a 




A facility not mentioned above that is 
designated for treatment of 30 days or 
longer and facility type is not Unknown 
Unknown  Patient known to be a resident of a long-
term care facility, but the type of facility 
is not known 
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Examples: Residential Facility 
· Assisted living facilities 
· Homes for mentally retarded or developmentally disabled persons 
· Boarding and care homes (e.g., residential care homes, group homes, homes for the aged, family 
care homes, adult foster care homes, personal care homes, adult congregate living facilities, 
residential community care facilities, domiciliary care homes) 
Examples: Mental Health Residential Facility 
· State and local mental hospitals 
· Private psychiatric hospitals 
· General hospitals (not federal) with separate psychiatric services  
· Department of Veterans Affairs (VA) medical centers 
· Residential treatment centers for emotionally disturbed children 
· Multiservice mental health organizations with residential treatment programs 
Note: Update this item if additional information is obtained during the course of treatment. 
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Primary Purpose: Surveillance. Data are used to determine if certain primary occupations are 
associated with TB disease. 
Select one option that best describes the patient’s occupation within the 12 months before the diagnostic TB 
evaluation. If the patient held more than 1 occupation during that period, select the longest-held  
occupation or the occupation to which the patient devoted more time (i.e., the patient’s primary  
occupation). For example, if the patient was a full-time health care worker and a student (e.g., taking 






Paid or unpaid person working in a health care setting, with potential for  
exposure to M. tuberculosis. For health care workers being evaluated for TB 




Person working in a correctional facility; not a health care worker 
Migrant/seasonal 
worker 
Person who is required to be absent from a permanent place of residence for the 
purpose of seeking employment, or who may vary their employment for the 
purpose of remaining employed while maintaining a permanent place of 
residence 
Other occupation Person employed for pay or income in any occupation that is not included in the 
options listed above 
Retired Person who was retired during the 12 months before the TB diagnostic 
evaluation 
Unemployed Person not employed during the 12 months before the TB diagnostic evaluation 
Not seeking 
employment 
Person not seeking employment, such as infant, child, student, homemaker, 
person receiving permanent disability benefits, or person who was 
institutionalized 
Unknown Person whose employment status is not known 
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Examples: Health Care Worker 
Includes full time, part-time, temporary, or contract staff. Examples include:  
· Physicians 
· Nurses 
· Health Aides 
· Dental workers 
· Health Technicians 
· Staff in laboratories and morgues 
· Emergency medical personnel 
· Students 
· Persons who deliver health care in the community 
(e.g., public health nurse, visiting nurse, outreach 
worker) 
· Persons not involved directly in patient care, but 
potentially at risk for occupational exposure  
(e.g., volunteers; outreach workers; 
dietary/nutritional, housekeeping, maintenance, 
clerical, janitorial, administrative and supervisory 
staff) 
Examples: Correctional Facility Employee 
· Federal or state prison 
· Local jail 
· Juvenile correctional facility 
· Immigration and Customs Enforcement (ICE) detention center or other correctional facility  
(See Resident of Correctional Facility [item 28].) 
· Paid or unpaid persons working in correctional facilities, with potential for exposure to M. 
tuberculosis complex (e.g., volunteers; outreach workers; dietary/nutritional, housekeeping, 
maintenance, clerical, and janitorial staff) 
Examples: Migrant/Seasonal Worker 
· Migratory agricultural worker 
· Seasonal agricultural worker 
· Migrant factory worker 
· Migrant construction worker 
· Migrant service industry worker 
· Migrant sporting worker (e.g., horse racing, dog racing) 
 
Comment: Unemployed 
Select Unemployed if a person not included in the preceding list was unemployed for most of the past 12 
months. Do not select this option for a person who was unemployed for a short time (e.g., 1 week  
during the past 12 months). 
Note: Update this item if additional information is obtained during the course of treatment. 
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31. Injecting Drug Use Within Past Year   
 
Primary Purpose: Surveillance. Data are used to determine the extent to which injecting drug use is 




No Patient has not injected drugs within the past 12 months. 
Yes Patient is known to have injected drugs within the past 12 months 
Unknown It is not known whether the patient injected drugs within the past 12 months 
Comment: Injecting Drug Use 
Medical documentation or other indications of enrollment in a drug treatment program (e.g., methadone 
detoxification; methadone maintenance; outpatient, residential, or inpatient treatment, halfway house; 
prison or jail treatment; Narcotics Anonymous, Cocaine Anonymous, or other self-help program), 
medical or laboratory documentation of injection drug use (e.g., urine testing), or physical evidence (e.g., 
needle tracks) may be useful in answering this question. Because many patients respond negatively during 
the interview, it may be necessary to ask the patient about drug use at multiple visits.  
Comment: Definition of Injecting Drug Use 
Injecting drug use involves the use of hypodermic needles and syringes for the injection of drugs not 
prescribed by a health care provider. Route of administration may be intravenous, subcutaneous (e.g., skin 
popping), or intramuscular. 
Note: Update this item if additional information is obtained during the course of treatment. 
Examples: Commonly injected drugs 
· Heroin and other opiates (e.g., 
Demerol, Dilaudid, morphine, opium) 
· Cocaine (e.g., speedball) 
· Methamphetamines 
· Amphetamines 
· Other stimulants 
· Phencyclidine (PCP, also known as angel dust) 
· Other hallucinogens 
· Barbiturates 
· Steroids 
· Other hormones 
· Fentanyl 
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32. Non-Injecting Drug Use Within Past Year  
 
Primary Purpose: Surveillance. Data are used to determine the extent to which non-injecting drug use 




No Patient has no history of using non-injecting drugs within the past 12 months 
Yes It is known that the patient has used non-injecting drugs within the past 12 months. 
Unknown It is not known whether the patient used non-injecting drugs within the past 12 
months. 
 
Comment: Non-Injecting Drug Use 
A history of enrollment in a drug treatment program (e.g., outpatient, residential, or inpatient treatment; 
halfway house; prison or jail treatment; Cocaine Anonymous or other self-help program), as well as 
medical or laboratory documentation of drug use (e.g., urine testing), may be useful in answering this 
question. Because many patients respond negatively during the interview, it may be necessary to ask the 
patient about drug use at multiple visits. 
Comment: Definition of Non-Injecting Drug Use 
Non-injecting drug use involves the use of licensed or prescription drugs or illegal drugs that were not 
injected and were not prescribed for the patient by a health care provider. The drugs may be ingested, 
inhaled, sniffed, or smoked. 
Note: Update this item if additional information is obtained during the course of treatment. 
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Examples: Non-injecting drugs 
· Heroin or other opiates (e.g., Demerol, Percocet, codeine, Dilaudid, MS Contin, nonprescription 
methadone) 
· Cocaine (e.g., snorted) and crack (e.g., smoked) 
· Ingested amphetamines (e.g., speed, uppers, bennies) 
· Xanax, Ativan, Valium, or other benzodiazepams 
· Phencyclidine (PCP), ketamine, LSD, or other hallucinogens 
· Barbiturates 
· Marijuana (e.g., pot, weed, grass, reefers), hashish 
· Inhalants (e.g., nitrous [whippets] oxide, poppers, rush, huff, gasoline, spray paint, butane) 
· Steroids 
Note: Alcohol is not included as a non-injecting drug (see Excess Alcohol Use within Past Year 
[item 33]). 
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33. Excess Alcohol Use Within Past Year  
 
Primary Purpose: Surveillance. Data are used to determine the extent to which excess alcohol use is 




No Patient has not used alcohol to excess within the past 12 months. 
Yes Patient has used alcohol to excess within the past 12 months. 





This information is collected because the patient is in a high risk group for TB. The patient’s response to 
this question is sought as an indicator of recent excess alcohol use. Because many patients respond 
negatively during the interview, it may be necessary to ask the patient, at multiple visits, about excess use. 
Note: Update this item if additional information is obtained during the course of treatment. 
Definition of Excess Alcohol Use: There is no standard definition. Excess alcohol use can be assessed by 
various methods. Examples of reliable indicators of excess alcohol use include: 
· Participation in self-help programs (e.g., Alcoholics Anonymous) or alcohol treatment programs 
· Medical record documentation of excess alcohol use or hospitalization for alcohol-related 
medical conditions (e.g., delirium tremens [DTs], pancreatitis, cirrhosis) 
· More than one arrest for intoxication or drunk and disorderly behavior. This can be found by 
asking the patient, or contacting the local correctional facility regarding charges. 
The National Household Survey on Drug Abuse defines heavy alcohol use as “five or more drinks on the 
same occasion on each of 5 or more days in the past 30 days.” Numerous screening instruments (e.g., 
CAGE, AUDIT, MAST) can be helpful in identifying persons who may use alcohol to excess. 
A standard drink in the United States is equal to 13.7 grams (0.6 ounces) of pure alcohol or 
· 12 ounces of beer 
· 8 ounces of malt liquor 
· 5 ounces of wine 
· 1.5 ounces or a “shot” of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey) 
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Primary Purpose: Surveillance. Data are used to evaluate how these additional risk factors are 
associated with TB disease. 
 
Select all additional TB risk factors that the TB patient may have. Document additional TB risk factors 
from the medical records or a reliable source (e.g., health care provider). Undocumented reporting (e.g., 
oral report from the patient or person other than a medical health care provider) is not acceptable.  
Note: Other specific TB risk factors (e.g., occupation, HIV infection) are collected through other items 
of the RVCT. 
Option 
(select all that 
apply) 
Description 
Contact of MDR TB 
patient  
(2 years or less) 
Patient for whom the RVCT form is being completed is a contact of a  
patient with multidrug-resistant (MDR) TB, within 2 years or less, regardless 
of whether the patient with MDR TB was infectious.   
Contact of infectious 
TB patient  
(2 years or less) 
Patient for whom the RVCT form is being completed is a contact of an 
infectious TB patient within 2 years or less. 
Missed contact  
(2 years or less) 
Patient for whom the RVCT form is being completed is a contact of a known 
TB patient, but was not evaluated or diagnosed with LTBI or TB at that time 
(within 2 years or less of current diagnosis).  
Incomplete LTBI 
treatment 
Patient had a previous diagnosis of latent TB infection (LTBI) and did not 
complete treatment for LTBI. 




Patient had recently received, or was receiving, TNF-α antagonist therapy at 
the time of TB diagnosis. 
Post-organ 
transplantation 
Patient has received a solid organ transplant (e.g., kidney, heart). 
Diabetes mellitus  Patient has a diagnosis of diabetes mellitus (Type I or Type II) either before or 
at the time of TB diagnosis.  
End-stage renal 
disease 
Patient had end-stage renal disease or chronic renal failure at the time of  
TB diagnosis. 
 99 
Immunosuppression Patient had immunosuppression due to either a medical condition or  
medication, such as hematologic or reticuloendothelial malignancies  
(e.g., leukemia, Hodgkin’s lymphoma, carcinoma of the head or neck),  
or immunosuppressive therapy, such as prolonged use of high-dose  
adrenocorticosteriods (e.g., prednisone). 
Other Patient had a risk factor not included in the preceding choices (e.g.,  
undernutrition due to intestinal bypass surgery for obesity, gastrectomy, 
jejunoileal bypass, chronic malabsorption syndromes; silicosis; travel to a TB-
endemic country). 
None No TB risk factors could be identified. 
Comments: Contact of MDR TB Patient 
· MDR TB is defined as resistance to at least isoniazid and rifampin.
 
· If a patient with MDR TB was the only known contact for the patient for whom you are 
completing the RVCT, select Contact of MDR TB Patient and do not select Contact of 
Infectious TB Patient. The association between the TB patients may have been found through 
investigation (e.g., a formal contact investigation) or identified as an incidental finding. 
· The contact with the patient with MDR TB must have been within the last 2 years. 
· If the patient with MDR TB has an RVCT number, enter that number as the Linking State Case 
Number (item 3), and enter reason 2 - Epidemiologically Linked Case. 
Comments: Contact of Infectious TB Patient 
· If the infectious TB patient is known to have had MDR TB, and the TB patient for whom the 
RVCT form is being completed was not a contact of any other infectious TB patient, select only 
Contact of MDR TB Patient (do not select Contact of Infectious TB Patient).
· The association between the TB patients may have been found through investigation (e.g., a 
formal contact investigation) or as an incidental finding. The contact with an infectious TB 
patient must have been within the last 2 years. 
 
· If the infectious TB patient has an RVCT number, enter that number as the Linking State Case 
Number (item 3), and enter reason 2 - Epidemiologically Linked Case 
Comment: Missed Contact 
The contact must have been within the last 2 years. Do not select this option for TB patients identified as 
having TB disease during, or as a result of, a contact investigation: such patients are not missed contacts. 
Here, the intention is to record information about patients whose TB could have been prevented if they 
had been identified before developing TB disease. 
Comment: Incomplete LTBI Treatment 
The intention is to record information about a patient who started treatment for LTBI. However, the
patient did not complete a full course of treatment.
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Comment: Tumor Necrosis Factor-alpha (TNF-α) Antagonist Therapy 
The Food and Drug Administration (FDA) has approved TNF-α antagonist therapy for treatment of 
rheumatoid arthritis and other selected autoimmune diseases. The FDA has also recently determined that 
TB disease is a potential adverse reaction to treatment with TNF-α antagonists. The three TNF-α 









· If the TB patient has diabetes mellitus or end-stage renal disease, check Diabetes Mellitus or 
End-Stage Renal Disease or both (do not select Immunosuppression unless the patient has 
another immunosuppressive condition). 
· If the patient is infected with HIV, complete HIV Status at Time of Diagnosis (item 26) (do not 
select Immunosuppression unless the patient has another immunosuppressive condition). 
Comments: Other 
Do not include risk factors identified in items 27–33: 
· Being homeless within past year (item 27) 
· Residence status at diagnosis  
o Correctional facility (item 28) 
o Long-term care facility (item 29) 
· Primary occupation within past year (item 30) 
· Drug or excess alcohol use within past year (items 31–33) 
On the line labeled Specify, write comments regarding Other reasons. 
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Primary Purpose: Surveillance. Data are used to observe the association between immigration status 
and TB. 
Option Description 
Not applicable  Patient was  
· “U.S.-born”  
o Born in 1 of the 50 states or the District of Columbia  
or 
o Born abroad to a parent who was a U.S. citizen (e.g., born on a military 
installation) 
(See Item 12 for complete instructions on “U.S.-born”) 
· Born in 1 of the U.S. Territories, U.S. Island Areas, or U.S. Outlying 
Areas 
o American Samoa, Federated States of Micronesia, Republic of the 
Marshall Islands, Commonwealth of the Northern Mariana Islands, 
Republic of Palau, Guam, Puerto Rico, or the U.S. Virgin Islands  
If you did not select Not Applicable, select one option to indicate the patient’s immigration status at first 
entry to the United States. 
Note: If the patient had a visa at first entry to the United States, specify the type of visa. Oral  
information from a reliable source is acceptable. 
There are 2 main types of legal immigration status: permanent (immigrants) and nonimmigrant 
(persons with a visa issued for specific purpose and period). 
1. Permanent residents (immigrants) are issued an alien resident card (i.e., green card) and should 
carry this card with them. 
2. Nonimmigrants with visas (e.g., student, tourist, employment, V visa, K visa) should be aware of 
their visa type, which is stated in their passport (I-94 arrival document stapled in passport). 
Refugees are separate from the 2 main categories above: they should have an arrival document  







For foreign-born TB patients who first entered the United States with permanent 
resident status (immigrants).  
For foreign-born pediatric TB patients who are adopted by U.S. citizens, the patients 
enter the U.S. on an immigrant visa.  
Student visa For foreign-born TB patients who first entered the United States with a student visa. 
This is a nonimmigrant visa and is obtained by an alien coming to the United States 
for a specific period to pursue a full course of study in an approved institution. 
Employment 
visa 
For foreign-born patients who first entered the United States with a nonimmigrant 
employment visa (an alien coming to the United States to work for a specific period). 
There are many categories of nonimmigrant employment visas (category depends 
upon the type of work). 
Tourist visa For foreign-born TB patients who first entered the United States for a specific  
period for business or pleasure. This is a nonimmigrant visa. 
Family/ fiancé 
visa 
For foreign-born TB patients who first entered the United States with a V visa or a  
K visa. 
Refugee For foreign-born TB patients who first entered the United States as refugees. 
Asylee or 
parolee 





For foreign-born TB patients who first entered the United States with a status that is 
not Immigrant, Refugee, Asylee, Parolee, Student, Tourist, Employment, with a V 
visa or a K visa, and whose status is not Unknown. This includes foreign-born 
persons who were not required to obtain a visa (e.g., foreign-born visitors from 
specific countries, such as Canada, that are part of the U.S. visa waiver program and 
thus are not required to obtain visas if visiting the United States for short periods 
[e.g., <90 days]) or those who entered the United States with no official immigration 
status (e.g., they were “undocumented”). 
Unknown For jurisdictions with directives or policies that forbid asking TB patients their  
immigration status 
· Foreign-born TB patients who  
o Do not know their immigration status at first entry to the United States 
o May have had a visa at entry to the United States, but the type of visa is 
unknown 
· Patients who refuse to respond 
Note: For jurisdictions with directives or policies that forbid asking TB patients their immigration 
status, please check Unknown. 
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Comments: Family/Fiancé Visa 
· The V visa (in the nonimmigrant category) allows the spouse or child of a U.S. legal permanent 
resident to live and work in the United States. 
· The K visa (in the nonimmigrant category) allows the fiancé of a U.S. citizen to enter the United 
States for a specific period and specifically for the purpose of marriage.
Comment: Refugee  
A refugee is a foreign-born person who is in a country other than his or her country of nationality and 
who is unable or unwilling to return to that country because of persecution or a well-founded fear of 
persecution. 
Comments:  Asylee and Parolee
An asylee is a foreign-born person in the United States who is unable or unwilling to return to his or her 
country of nationality because of persecution or a well-founded fear of persecution. An asylee meets the 
same criteria as those for a refugee; the only difference is the person’s location at the time of 
application—the potential asylee is in the United States or applying for admission at a port of entry, and 
the potential refugee is outside the United States. 
A parolee is a foreign-born person allowed to enter the United States for urgent humanitarian reasons or 
because entry is determined to be of significant public benefit. 
Comment: Born in 1 of the U.S. Territories, U.S. Island Areas, or U.S. Outlying Areas  (American 
Samoa, Federated States of Micronesia, Republic of the Marshall Islands, Commonwealth of the Northern 
Mariana Islands, Republic of Palau, Guam, Puerto Rico, or the U.S. Virgin Islands)  
Example: For born in 1 of the U.S. Territories, U.S. Island Areas, or U.S. Outlying Areas select  
not applicable for  
· Entering the United States 
or 
· Entering one of the other U.S. Territories, U.S. Island Areas, or U.S. Outlying Areas  
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36. Date Therapy Started  
 
Primary Purpose: Programmatic function. Data are used for calculating program management 
indicators. 
Description Comment 
Month, day, and year 
(e.g., 01/17/2009) 
Date the patient began multidrug 
therapy for TB disease or 
suspected TB disease 
This may be one of several dates, 
ideally, when the patient first ingested 
medication if documented in a 
medical record.  
If the month or day is unknown, enter 
99 as the default value (e.g., 
01/99/2009). 
Date Therapy Started is the month, day, and year the patient began multidrug therapy for TB disease or 
suspected TB disease. Patient history without medical documentation is not acceptable and should be 
entered as unknown. Enter a date according to the following chart:
Hierarchy of Determining Date Therapy Started 



















Medication was First Dispensed to the Patient 
as documented by medical or pharmacy record 
Date  
Medication was First Prescribed to the Patient 
 by the Health Care Provider  
as documented by medical or pharmacy record  
 
Date  
Patient First Ingested Medication  
if documented in a medical record, such as hospital, or 
clinic, or directly observed therapy (DOT) record (preferred) 
 
Preferred  
Date Therapy Started 
If this date is not known  
choose the next alternative 
 
 
Next Alternative  
Date Therapy Started 
If this date is not known  
choose the last alternative 
Last Alternative  
Date Therapy Started 
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37.  Initial Drug Regimen 
 
Primary Purpose: Programmatic function. Data are used for calculating program management 
indicators. 




No Drug is known to not be part of the initial regimen. 
Yes Drug is known to be part of the initial regimen. 
 
Yes indicates that the drug was initially prescribed 
for treatment of TB disease and was taken for at 
least 2 weeks. The 2-week requirement should 
eliminate most of the record updates necessitated 
by changes in regimen after treatment has begun.  
If you cannot determine the 
initial regimen of at least 2 
weeks’ duration, select Yes 
for the initial drugs known to 
have been prescribed. 
Unknown It is not known whether the drug was part of the 
initial regimen. 
Comment: Combination drugs 
For combination drugs, select Yes for each drug that is a component of the combination drug. 
For example 
· Rifamate is a combination of izoniazid and rifampin 
· Rifater is a combination of izoniazid, rifampin, and pyrazinamide 
Example: Combination drugs 
For Rifamate, select Yes for isoniazid and Yes for rifampin.
 
Note: For Other, enter only anti-TB drugs (do not include pyridoxine, vitamin B6). 
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 Initial Drug Susceptibility Report (Follow Up Report – 1)  
(page 1 of 1) 
Items 38 – 40 
Page 1 of the Initial Drug Susceptibility Report (Follow Up Report  – 1) provides instructions for 
completing items 38 – 40. This page is a follow-up report to the RVCT and includes data about 
genotyping, as well as initial drug susceptibility testing and results.  
Complete this report only for cases with positive culture results for M. tuberculosis complex.  
Complete and submit this report as soon as initial drug susceptibility results are available. Copy patient 
name and address from page 1 of the RVCT. The patient name and address are retained at the local level 
for identification purposes; they are not sent to CDC. Enter Year Counted, State Case Number, and 
City/County Case Number for data entry purposes. 
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No No isolate was submitted for  
genotyping. 
No does not indicate that no results were 
received or that “untypeable” results were 
reported. 
Yes Isolate was submitted for genotyping, 
regardless of genotyping results. 





The genotyping accession number for 
the current TB episode. This number 
is assigned by the genotyping 
reference laboratory. 
If multiple isolates have been submitted for 
one patient, please consult with your 
laboratorian or genotyping surveillance 
coordinator to determine the correct 
genotyping accession number for the current 
episode. 
Comment: Genotyping accession number 
In 2004, CDC established the National Tuberculosis Genotyping Service (NTGS). The goal was to 
genotype one M. tuberculosis isolate from every culture-confirmed TB case in the United States. The 
genotyping accession number is the number assigned by the genotyping reference laboratory. Under 
current contracts, the numbers are formatted in the following table. 
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Format for  
Genotyping Accession Number 
Sample 
California lab YY (the 2-digit year), followed by L and 4 digits 05L1234 
Michigan lab YY (the 2-digit year), followed by RF and 4 digits 06RF5678 
CDC lab YY (the 2-digit year), followed by a hyphen and 6 digits 06-012345 
When entering the genotyping accession number, begin at the first box and continue to fill to the right. 
Include all hyphens and letters. Do not add zeros in the remaining boxes (beyond the number provided by 
the reference lab). 
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39. Initial Drug Susceptibility Testing   
 
 
Primary Purpose: Programmatic function. Data are used to monitor the rate of susceptibility testing 




No Initial drug susceptibility testing was not performed. 
          
Yes An initial isolate was obtained, submitted for drug susceptibility testing, and 
results are available. 
Unknown  It is not known whether initial drug susceptibility testing was performed. 
Comments:  
If drug susceptibility testing was performed on multiple initial isolates, select one of the following (there is 
no hierarchy for selecting these options):  
· The isolate associated with the primary, or major, site of disease 
or 
· The initial isolate from the major site of disease that yields the best or most information concerning 
drug susceptibility results 
or 
· The initial culture-positive isolate. 
Note: If the answer is No or Unknown, do not complete the remainder of this form (Initial Drug 
Susceptibility Report [Follow Up Report–1]). 
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If you selected Yes, enter the following information.
Description Comment 
Date first specimen  
for which drug 
susceptibility testing 
was done 
Month, day, and year the first 
specimen was collected 
(e.g., 01/17/2009) 
If the month or day is unknown, enter 
99 as the default value (e.g., 
01/99/2009). 





Not sputum Enter appropriate anatomic code (e.g., 30 for pericarditis) from the Anatomic 
Code list (see Appendix C – Anatomic Codes). 
 
Note: For the purposes of the RVCT training materials, use the codes listed in the appendices. Some 
software programs used to enter data on the RVCT may NOT use the codes listed in the appendices. 
For example, the Anatomic Codes may be a drop-down item, where you choose the actual site rather 
than enter a code. For more information, see instructions for the software you use. 
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Primary Purpose: Programmatic function. Data are used to monitor trends in drug resistance and 
calculate indicators. 
 
Record the results of initial drug susceptibility testing on the first specimen on which drug susceptibility 
testing was performed. If drug susceptibility testing was performed on multiple initial isolates, select one 
of the following (there is no hierarchy for selecting these options):  
· The isolate associated with the primary, or major, site of disease 
or 
· The initial isolate from the major site of disease that yields the best or most information 
concerning drug susceptibility results 
or 
· The initial culture-positive isolate.  
Note: Report results from conventional drug susceptibility tests (DST) only. Do not report rapid DST 
test results (molecular beacon, molecular line probe assays, or other molecular tests).  
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First-line and Second-line Anti-TB Drugs 
 
















· Other Quinolones 
· Cycloserine 




· If drug susceptibility testing for first-line anti-TB drugs was performed on a specific specimen 
and resistance to one or more drugs was noted, thus prompting drug susceptibility testing for 
second-line anti-TB drugs, this testing should be done on the same specimen. Enter both first- and 
second-line testing results for this variable, even if the results are received at different times. 
 
· If the same specimen is used for drug susceptibility testing for second-line anti-TB drugs after 
testing for first-line anti-TB drugs, update these variables when results become available. 
· If a second specimen is needed for drug susceptibility testing for second-line anti-TB drugs, the 
second specimen should be collected as soon as possible after the first specimen was collected for 
drug susceptibility testing for first-line anti-TB drugs (i.e., interval between specimen collections 
should be less than 4 weeks). Update these variables when results become available. 




Resistant Drug has any degree of resistance (even partial resistance, resistance at a low 
concentration of the drug, or a result other than completely susceptible). 
Susceptible Select only if completely susceptible. 
Not done Susceptibility testing was not done for this drug. 
Unknown It is not known whether the test was performed. 
          or 
Results are not available or result is not known for a reason other than pending 
results. 
Note: Other Quinolones excludes ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin  
because they are listed on the form. 
 
Use the space at the bottom of the form to write comments (e.g., name of the laboratory that  
performed drug susceptibility testing) regarding the case of TB reported on this form (Initial Drug 
Susceptibility Report). 
 
If radiometric and conventional results on the same specimen differ (e.g., one is resistant, the other is 
susceptible), discuss the results with your state TB laboratory director and complete the item 
accordingly.  
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Comment: Combination drugs 
For combination drugs (e.g., Rifamate, Rifater), select Yes for each drug that is a component of the 
combination drug. 
For example 
· Rifamate is a combination of izoniazid and rifampin 
· Rifater is a combination of izoniazid, rifampin and pyrazinamide 
Example: Rifamate 
For Rifamate, select Yes for isoniazid and Yes for rifampin.
Note: For Other, enter only anti-TB drugs (do not include pyridoxine, [vitamin B6]). 
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Case Completion Report (Follow Up Report – 2)  
Items 41 – 49 
Pages 1 and 2 of the Case Completion Report (Follow Up Report – 2) provide instructions for completing 
items 41 – 49. This 2-page report includes data about treatment outcomes, provider status, and if the 
patient moved during treatment.   
Complete this form for all patients who were alive at the time of TB diagnosis. Enter data as soon as 
information becomes available during patient follow-up. This report should be completed when the case 
is closed to supervision and is due no later than 2 years after the initial RVCT.  
Copy patient name and address from page 1 of the RVCT form. Patient name and address are retained at 
the local level for identification purposes; they are not sent to CDC. Enter Year Counted, State Case 
Number, and City/County Case Number for data entry purposes. 
(page 1 of 2) 
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(page 2 of 2) 
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Primary Purpose: Programmatic function. Data are used to monitor the rate of sputum culture 
conversion. 
Provide information on sputum culture conversion only for patients with initially positive sputum 
cultures. Sources for documentation of sputum culture conversion include patient medical records and 
laboratory reports. 
Note: Do NOT complete this item for patients whose –  
 
· Sputum culture was not indicated as positive in Sputum Culture (item 18). 
 
· Initial sputum specimen did not test positive and whose other pulmonary specimens (e.g., 




No Initial sputum specimen was 
culture-positive; no later specimens 
were culture-negative (e.g., all 
follow-up cultures were positive, 
patient could not produce sputum 
after therapy started, or no follow-
up sputum cultures were obtained). 
 
Yes Initial sputum specimen was 
culture-positive, followed by at 
least 1 negative sputum culture. 
There should be no positive cultures after the 
negative culture(s). 
Unknown Results of all follow-up cultures are 
not known. 
          or 
It is not known whether follow-up 
cultures were done. 
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If you selected Yes, enter the following information.
Description Comment 






Month, day, and year when the 
first of the consistently negative 
sputum specimens was 
collected (e.g., 01/17/2009). 
Complete only for patients who had 1 or more 
positive sputum cultures and who 
subsequently had at least 1 documented 
negative culture. 
 
This date should be at least 1 week after the 
last positive culture result. There should be no 
positive cultures after this date. 
 
This information may be available from 
medical records or laboratory reports. 
 
If the month or day is unknown, enter 99 as 
the default value (e.g., 01/99/2009). 







Repeat sputum collection was attempted (including induced sputum collection), 
but because of clinical improvement, patient was not able to produce sputum. 
No follow-up  
sputum and no 
induction 
Induction was not attempted (e.g., the health care provider did not order a repeat 
specimen, or there were no facilities or equipment for induction). 
Died  Patient died before having an opportunity to submit sputum to document whether 
the sputum culture had converted. 
Patient lost to 
follow-up 
Patient was lost to follow-up before having an opportunity to submit a sputum to 
document whether the sputum culture had converted. 
Patient refused Patient refused to provide a sputum specimen for a repeat culture. 
Other  
(specify) 
A reason not included in the above choices (e.g., treatment failed, or the patient 
moved outside the United States). 
Unknown  It is not known why a repeat sputum culture was not obtained. 
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Primary Purpose: Programmatic function. Data are used to facilitate efficient communication between 
TB control programs in providing continuity of care for the patient. 
This variable is used to record whether the patient moved during TB therapy. The responsibility for 
follow-up reporting generally remains with the reporting area that initially reported the case to CDC and 
counted it. (For a detailed description of the responsibility for submitting follow-up reports to CDC, see 
the instructions for Reporting Address for Case Counting [item 4].) 
 




No Patient did not move. 
          or 
Patient moved within the same local health department jurisdiction. 
Yes Patient moved to an area where another jurisdiction must now provide or 
coordinate TB care. 
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If you selected Yes, select all the options that apply to the area to which the patient moved. 
Option 





Patient moved within the state, but 
out of the local heath department 
jurisdiction, such as moved to 
different county or city. 
Enter the city or county health 
department jurisdiction to which the 
patient moved.  
If the patient moved more than 
twice, enter the first 2 moves. 
Out of state  
(specify) 
Patient moved from 1 of the 50 U.S.  
states or the District of Columbia to  
· Another state (e.g., moved from 
Georgia to Alabama)  
or  
· A U.S. Territory, U.S. Island 
Area, or U.S. Outlying Area  
If the patient moved more than 
twice, enter the first 2 moves.  
Patient moved from a U.S. Territory, 
U.S. Island Area, or U.S. Outlying 
Area to  
· One of the 50 U.S. states or the 
District of Columbia 
or 
· A U.S. Territory, U.S. Island 
Area, or U.S. Outlying Area   
 
Enter the name of the state or 
reporting area to which the patient 
moved. 
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Out of the U.S. 
(specify) 
Patient moved from the United States 
to  
· Another country (other than a 
U.S. Territory, U.S. Island Area, 
or U.S. Outlying Area) 
If the patient moved more than 
twice, enter the first 2 moves. 
Moved from a U.S. Territory, U.S. 
Island Area, or U.S. Outlying Area to 
· Another country (other than the 
United States or another U.S. 
Territory, U.S. Island Area, or 
U.S. Outlying Area)  
Enter the name of the country to 
which the patient moved. 




 that apply) 
Description Comment 
No Referral was not made to 
a TB program or 
physician outside the 
United States. 
Transnational referral includes participation in 
programs such as  
· TBNet 
· CureTB 
· Immigration and Customs Enforcement (ICE) 
 
Communication between programs is important    
· To help ensure case management after 
deportation 
· For completing a case management transfer 
and obtaining information from TB programs 
and/or physicians outside the United States for 
case completion 
For more information, visit the CDC/DTBE  web 
site on the Process for Notification of TB Cases at 
www.cdc.gov/tb/pubs/international/default.htm 
Yes Referral was made to a 
TB program or physician 
outside the United States. 
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Example: Moved within a county, parish, or within a state 
A move could be within a county, parish, or even within a state provided that the same health department 
jurisdiction is primarily responsible for providing the TB case management, completing the RVCT, and 
ensuring the completion of treatment.
 
Example: New York City 
New York State and New York City (NYC) are separate TB reporting areas that report TB cases directly 
to CDC. If a patient moves from New York State to NYC or vice versa, the move is considered “in-state, 
out of jurisdiction.” Select In-state, out-of jurisdiction. 
 
Example: Reporting from one of the U.S. Territories, U.S. Island Areas, or U.S. Outlying Areas 
If you are reporting from one of the U.S. Territories, U.S. Island Areas, or U.S. Outlying Areas 
(American Samoa, Federated States of Micronesia, Guam, Republic of the Marshall Islands, 
Commonwealth of the Northern Mariana Islands, Republic of Palau, Puerto Rico, or U.S. Virgin Islands), 
select Out of state if a patient moves out of your reporting area to the United States or to another U.S. 
Territory, U.S. Island Area, or U.S. Outlying Area.  
However, if a patient moves from your jurisdiction to a country other than the United States or another 
U.S. Territory, U.S. Island Area, or U.S. Outlying Area, select Out of the U.S. 
Examples of Moved  
Moved Select 
From To 
Dallas County, Texas Harris County, Texas In-state, out-of jurisdiction  
Denali Borough, Alaska Bethel Borough, Alaska In-state, out-of jurisdiction 
Orleans Parish, Louisiana Vernon Parish, Louisiana In-state, out-of jurisdiction 
Chuuk, Federated States of 
Micronesia (FSM) 
Yap, FSM In-state, out-of jurisdiction 
California Hawaii Out of state 
Washington, D.C. Baltimore, Maryland Out of state 
California Guam Out of state 
Guam Palau Out of state 
Guam Hawaii Out of state 
Chuuk, FSM Guam Out of state 
Chuuk, FSM California Out of state 
Puerto Rico Florida Out of state 
Guam China Out of the U.S. 





43. Date Therapy Stopped 
 
Primary Purpose: Programmatic function. Data are used to monitor completion of therapy within a 
specified time.  
Description Comment 
Month, day, and 
year 
(e.g., 01/17/2005) 
Date the patient stopped taking 
therapy for TB disease or 
suspected TB disease 
This may be one of several dates, ideally, 
when the patient last ingested medication if 
documented in a medical record. 
If the month or day is unknown, enter 99 as 
the default value (e.g., 01/99/2005). 
Comment: Date Therapy Stopped 
The interval between Date Therapy Started (item 36) and Date Therapy Stopped (item 43) is meant to 
encompass the entire period (including interruptions in therapy) that the patient was receiving medication 
to treat TB disease or suspected TB disease. Patient self-report without medical documentation is not 
acceptable. Although there may be interruptions in anti-TB drug therapy, enter the final documented date 
on which the patient last ingested medication for TB disease or suspected TB. For patients being treated 
for TB disease or suspected TB disease, enter Date Therapy Stopped, according to the following chart: 
Hierarchy for Determining Date Therapy Stopped  

















Patient Last Ingested Medication 
 
Date  
Medication Dispensed to the Patient  
Would Have Run Out if the Patient had Taken 
All the Medication 
Date  
Medication Prescribed to the Patient Would 
Have Run Out if the Patient Had Taken All the 
Medication from the Date of Prescription  
(from the final prescription for the last bottle) 
Preferred  
Date Therapy Stopped 
If this date is not known, choose 
the next alternative date stopped 
 Next Alternative  
Date Therapy Stopped 
If this date is not known, choose 
the last alternative date 
Last Alternative  
Date Therapy Stopped 
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Comment: Update the date that therapy was stopped 
Update the date therapy was stopped only if a patient was lost to follow-up and then returns and 
completes therapy.  
Comment: Reopened case 
If a case is reopened (e.g., patient who has been lost to follow-up is found, restarts therapy, and then 
completes therapy), update this form (Case Completion Report [Follow Up – Report 2]) to reflect that the 
patient completed therapy. 
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44. Reason Therapy Stopped or Never Started 
 
Primary Purpose: Programmatic function. Data are used to document treatment outcome. 
Complete this item when the patient completes therapy or the case is closed. Select the primary reason 






Patient completed the prescribed course of therapy per the medical record as 
recorded by the clinician caring for the patient. 
Lost  Patient could not be located before the start or the completion of treatment (e.g., the 
patient moved to an unknown location, or the forwarding address is known but the 
patient was not found at that address). 








Therapy was permanently stopped because of an adverse event due to anti-TB 
medications. Select this option only if the patient lived.  
If the patient died because of an adverse TB treatment event, select  
· Died as the Reason Therapy Stopped  
and then select 
· Related to TB Therapy for Cause of Death even if the patient stopped TB 
therapy prior to the death due to an adverse treatment event.  
This is a determination that has to be made by the clinician. 
Not TB Completed diagnostic evaluation did not substantiate the diagnosis of TB (e.g., M. 
avium was isolated from a clinical specimen). 
Died  Patient was alive at diagnosis but died before the start or completion of treatment.  
This also applies to a patient classified as alive for Status at TB Diagnosis (item 15) 
if the patient was taking at least 2 anti-TB drugs before the day of death, even though 
the TB case was not verified and counted until after death. 
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Other  Therapy was discontinued for a known reason not included in the above choices and 
is not Unknown, (e.g., patient moved outside the United States, or patient moved 
from state A to state B, and state A notified state B, but state B never followed up). 
Unknown Reason that therapy was stopped is not known. 
Comment: Reopen a case   
If a case is reopened (e.g., patient who has been lost to follow-up is found within 12 months of when the 
patient was lost, restarts therapy, and then completes therapy), update this form (Case Completion Report 
[Follow Up – Report 2]) to reflect that the patient completed therapy. 




Related to TB 
disease 
TB was 
· The immediate cause 
or  
· An underlying cause 
or  
· Another significant condition 
contributing to death (even if 
TB was not the main cause of 
death) 
 
Written documentation of the cause of death 
(e.g., death certificate, autopsy report, medical 
records) is recommended. However, oral 
information from a reliable source (e.g., a 
health care provider) will be accepted. 
A death certificate is not necessarily required 
to complete this field. In some cases deaths 
may be certified before receipt of results of  
· Positive M. tuberculosis culture 
or 
· Other findings consistent with TB  
Classify as related to TB disease if the patient 
died as a result of a surgical procedure for 
which 
· The primary indication was the diagnosis 
of TB 
    or  
· TB complicated a surgical procedure not 
related to TB (e.g., heart surgery) 
 
Criteria for determining the cause of death 
related to TB disease should be specified by 
the clinician. 
Related to TB 
therapy 
TB therapy (e.g., adverse 
treatment event) was related to 
the cause of death.  
Criteria for determining the cause of death 
related to TB therapy should be specified by 
the clinician.  
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Unrelated to TB 
disease 
TB was not  
· The immediate cause 
or 
· An underlying cause 
or  
· Another significant condition 
contributing to death 
Unknown Cause of death is not known. Every effort should be made to determine if 
death was related to TB disease before 
classifying as unknown. 
Note: Update this item if additional information is obtained. 
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Primary Purpose: Program function. Data are used to document reason for extended treatment and to 
calculate program indicators. 
Use the information entered for Date Therapy Started (item 36) and Date Therapy Stopped (item 43) 
to calculate the length of anti-TB therapy. Sources for the reason(s) therapy was extended include patient 
medical records, patient interview, and health care provider interview. 
Option 
(select all that apply) 
Description Comment 
Rifampin resistance Patient had drug-resistant TB that 
would require a treatment protocol 
lasting more than 12 months (e.g., 
resistance to at least rifampin) 
according to the ATS/CDC/IDSA 
Official Joint Statement on the 
Treatment of TB. 
Adverse drug reaction Patient had a significant adverse drug  
reaction or experienced an adverse 
treatment event due to anti-TB 
medications that prolonged therapy.  
Non-adherence There were barriers to the patient’s  
adherence to anti-TB therapy (e.g., 
treatment interruption), or the patient’s 
lack of adherence resulted in extension 
of therapy beyond 12 months. 
Failure A sputum specimen tested positive 4 or 
more months after treatment began. 
Criteria for determining failure 




Clinical indications (other than 
adverse drug reactions) include 
central nervous system TB (e.g., 
meningitis), severe liver disease, or 
other criteria as specified by the 
clinician. 
Other Reason does not include any of the 
choices listed above. 
Use additional space at the 
bottom of the page to write 
comments regarding Other 
reasons. 
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Primary Purpose: Programmatic function. Data are used to guide TB programs in allocating 
resources. 
Definition for Type of Outpatient Health Care Provider:  setting or affiliation of the provider who has 
primary responsibility for clinical outpatient decision making (excluding diagnostic workup, contact 
investigations, anti-TB medications, and directly observed therapy [DOT]).
Note:  
· Outpatient refers to a setting that is not a hospital and that does not provide acute care, such as a 
clinic or a physician’s office.  
· Inpatient refers to a hospital or acute-care setting.  
 
Here, these terms refer to the physician, not to the patient. These terms also denote the type of services 
that are provided. Some institutions, such as a hospital, correctional facility, or long-term care facility, 
may have both outpatient and inpatient settings. 
Option 




Includes a TB program or a health clinic of a health department. 
Private outpatient Includes private physician or health care provider, health maintenance 
organization (HMO), and private managed health care provider. 
IHS, tribal HD, or tribal 
corporation 
Primary responsibility for clinical outpatient decision making rests with 
the Indian Health Service (IHS); a tribal health department, such as the 
American Indian or Alaska Native Tribal Health Department; or a tribal 
corporation, such as the Tribal Healthcare Corporation. 
Institutional/ 
correctional 
Includes nursing homes and assisted living facilities, and all types of 
correctional facilities. 
Inpatient care only Patient did not receive outpatient TB care. Care provided in a hospital. 
Other The provider is not included in the other categories and is not Unknown 
(e.g., state TB chest hospital providing outpatient care, city/county/state-
owned hospitals that are not part of the health department providing 
outpatient care, private hospital providing outpatient care, Veterans 
Administration hospital, federal program, military facility, or community-
based organization [CBO]). 
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Unknown Type of health care provider is not known. If you select Unknown, do not  
select any other option for type of health care provider. 
 
Comment: Private outpatient
This category includes the private provider who has the primary responsibility for clinical outpatient 
decision making for a TB patient, even though the TB control program or local/state health department 
may be periodically contacting the private provider for the purpose of completing the RVCT and  
ensuring proper TB case management.
Comment: Inpatient care only 
Examples of inpatient care only include 
· TB diagnosed at autopsy 
· Patients who were in the hospital but died before receiving outpatient TB care 
· Patients who received all of their TB care as an inpatient in a hospital 
Comment: Multiple options 
If a patient first received care from a private health care provider, but after a time (e.g., 3 months) lost his 
or her medical insurance and began receiving care from the local or state health department, select both 
Private and Local/State Health Department.
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Primary Purpose: Case management. Data are used to document administration of TB medications. 
Directly observed therapy (DOT), or supervised therapy, involves the direct visual observation by a health 
care provider (e.g., public health nurse, outreach worker, nurse, nurse’s aide) or other reliable trained 
person (e.g., worker in a homeless shelter) of a patient’s ingestion of medication. Delivering medication 
to a patient without visual confirmation of ingestion does not constitute DOT. However, a live video 
camera confirmation of ingestion of medicine of carefully selected patients (e.g., stable and compliant) 
constitutes DOT. 
 
Anti-TB medication may be  
1) Self-administered (e.g., patient ingests medication dose[s] without direct visual observation 
by a health care provider or other reliable person) 
or 
2) Given by using DOT  
or 




No, totally  
self-administered 
No doses of medication were given under direct supervision. 
Yes, totally directly 
observed 
Response applies if DOT was used for all doses for a patient who was taking 
medication 1–5 times a week. Response also applies if the patient was taking 
medication 7 times a week and DOT was used for at least 5 of those doses (i.e., 
patient self-administered the dose[s] during weekends and holidays). 
Yes, both directly 
observed and  
self-administered 
Response applies if the patient self-administered any dose while taking 
medication 1–5 times a week. Response does not apply if the patient was 
taking medication 7 times a week and DOT was used for at least 5 of those 
doses (i.e., patient self-administered the dose[s] during weekends and 
holidays). 
Response also applies if patient took several months of self-administered 
therapy and several months of DOT.  
Unknown It is not known whether any doses were given under direct supervision. 
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Number of weeks of 
directly observed 
therapy (DOT) 
Based on the total number of 
regimen-appropriate weeks and 
doses ingested under directly 
observed supervision (e.g., 026) 
The total number of DOT weeks must 
be less than or equal to the time 
between Date Therapy Started (item 
36) and Date Therapy Stopped (item 
43). 
To calculate Number of weeks of directly observed therapy (DOT weeks), use the following methods: 
· Review the patient’s medication records to determine the number of doses given by DOT  
each week 
Review the patient’s medication records to determine the number of doses given by DOT each 
week, or 7-day period. The number of days in a week is 7, but the calculation of DOT (or 
medication) weeks should be independent of, or not restricted to, calendar weeks (i.e., Sunday 
through Saturday). 
· Example: Medication week 
A medication week can be, for example, Monday through Sunday or Wednesday through 
Tuesday, as long as the week consists of 7 consecutive days. 
· Missed DOT dose 
If a patient misses a DOT dose or there is a holiday during a medication week (i.e., DOT cannot 
be given that week), as long as DOT is used when the missed dose(s) is made up at the end of 
therapy, the dose(s) given at the end of therapy can be combined with the last “partial DOT 
week” and counted as a “full DOT week.” 
 
· Count as a DOT week  
Count as a DOT week any week during which DOT was used for every dose for a patient who 
was taking medication 1–5 times a week. If the patient was taking medication 7 times a week, 
DOT must have been used for at least 5 doses.  
Often, the health department or the person completing the RVCT form does not have direct access to the 
entire patient medical record or medication log because the TB patient is or was cared for by a provider 
other than the health department (e.g., private health care provider). A private health care provider usually 
does not provide DOT; rather, a public health care provider (e.g., public health nurse) provides DOT and 
maintains the medication log and medication dosage calendar. The health department periodically follows 
up with the provider, and when therapy is completed or the case is closed, the health department usually 
completes a “close-out” form. In such instances, the health department should request a copy of the 
medication log or review the log with the person who provided DOT (e.g., public health nurse) to 
determine the amount of medication that was given by DOT. 
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No Follow-up drug susceptibility testing was not performed. 
Yes Drug susceptibility testing was performed on a specimen that was collected  
30 or more days after the specimen on which initial drug susceptibility testing 
was performed. 
Unknown It is not known whether follow-up drug susceptibility testing was performed. 
Comment:  
This variable will help assess the frequency of acquired drug resistance.




collected on which 
drug  
susceptibility 
testing was done 
Month, day, and year  
(e.g., 01/17/2009) 
This date should be 30 or more days after the 
collection date of the initial specimen on which 
drug susceptibility testing was done (item 39). 
This information is usually available from medical 
records or laboratory reports. 
 
If the month or day is unknown, enter 99 as the 
default value (e.g., 01/99/2009). 
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Not sputum Enter appropriate anatomic code (e.g., 30 for pericarditis) from Appendix C – 
Anatomic Codes 
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49. Final Drug Susceptibility Results   
 
 
Primary Purpose:  Programmatic function. Data are used to monitor trends in drug resistance.  
Record results for the final specimen on which drug susceptibility testing was performed. Drug 
susceptibility testing procedures should comply with approved and accepted guidelines. If drug 
susceptibility testing was performed on multiple specimens, select the most appropriate specimen: the one 
associated with the primary, or major, site of disease; the final specimen from the major site of disease that 
yields the best or most information concerning drug susceptibility results; or the final specimen that tested 
positive.  




Resistant Drug has any degree of resistance (even partial resistance or resistance at a low 
concentration of the drug, or other than completely susceptible result). 
Susceptible Select only if completely susceptible. 
Not done Susceptibility testing was not done for this drug. 
Unknown It is not known whether the test was performed. 
          or 
Results were not available or result is not known for a reason other than pending 
results. 
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Note: Other Quinolones excludes ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin  
because they are listed on the form. 
Use the space at the bottom of the form to write comments (e.g., name of the laboratory that  
performed drug susceptibility testing) regarding the case of TB reported on this form (Case  
Completion Report). 
If radiometric and conventional results on the same specimen differ (e.g., one is resistant, the other is 






The following appendices provide information and codes that are used to complete the RVCT:   
 
• Appendix A – Tuberculosis Case Definition for Public Health Surveillance  
 
• Appendix B – Recommendations for Reporting and Counting Tuberculosis 
Cases 
 
• Appendix C – Anatomic Codes 
 
• Appendix D – Reporting Area Codes 
 
• Appendix E – Country Codes 
 
• Appendix F – Glossary  
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Appendix A 
Tuberculosis Case Definition for Public Health Surveillance 
 
 
 (Revised May 13, 2009) 
 
Clinical description 
A chronic bacterial infection caused by Mycobacterium tuberculosis, usually characterized 
pathologically by the formation of granulomas. The most common site of infection is the lung, 
but other organs may be involved.  
 
Clinical case definition 
A case that meets all of the following criteria:  
• A positive tuberculin skin test result or positive interferon gamma release assay for M. 
tuberculosis 
• Other signs and symptoms compatible with tuberculosis (TB) (e.g., abnormal chest 
radiograph, abnormal chest computerized tomography scan or other chest imaging study, 
or clinical evidence of current disease) 
• Treatment with two or more anti-TB medications 
• A completed diagnostic evaluation 
 
Laboratory criteria for diagnosis  
• Isolation of M. tuberculosis complex from a clinical specimen,*  
or 
• Demonstration of M. tuberculosis complex from a clinical specimen by nucleic acid 
amplification test,†  
or 
• Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or 
cannot be obtained or is falsely negative or contaminated. 
 
Case classification 
Confirmed: a case that meets the clinical case definition or is laboratory confirmed 
 
Comment 
A case should not be counted twice within any consecutive 12-month period. However, a case 
occurring in a patient who had previously had verified TB disease should be reported and 
counted again if more than 12 months have elapsed since the patient completed therapy. A case 
should also be reported and counted again if the patient was lost to supervision for greater than 
12 months and TB disease can be verified again. Mycobacterial diseases other than those caused 
by M. tuberculosis complex should not be counted in tuberculosis morbidity statistics unless 
there is concurrent tuberculosis. 
 ______________________________                                     
*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid 
chromatography performed on a culture from a clinical specimen) are acceptable under this criterion. 
†Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical 
purposes. A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also 
genotyping. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the 
Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, 
or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement 
Amendments (CLIA) regulations.   
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Appendix B 
Recommendations for Reporting and Counting Tuberculosis Cases 
 
 
(Revised May 13, 2009) 
 
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”1 in 
July 1997, numerous changes have occurred, and many issues have been raised within the 
field of tuberculosis (TB) surveillance.  This current version updates and supersedes the 
previous version. 
 
A distinction should be made between reporting TB cases to a health department and 
counting TB cases for determining incidence of disease.  Throughout each year, TB cases 
and suspected cases are reported to public health authorities by sources such as clinics, 
hospitals, laboratories, and health care providers.  From these reports, the state or local TB 
control officer must determine which cases meet the current surveillance definition for TB 
disease and whether the case is countable.  These countable TB cases are then reported to the 
Centers for Disease Control and Prevention (CDC).   
 
Beginning in 2009, state and local TB control officers may also report to CDC those TB 
cases that are verified but not countable for morbidity statistics, as a measure of 
programmatic and case management burden. The noncountable report can include persons 
with TB disease recurring within a consecutive 12-month period after the patient completed 
TB therapy.  
 
I. Reporting TB Cases. CDC recommends that health care providers and laboratories 
be required to report all TB cases or suspected cases to state and local health 
departments based on the current “Tuberculosis Case Definition for Public Health 
Surveillance” (Appendix A). This notification is essential in order for TB programs to 
 
• Ensure case supervision 
• Ensure completion of appropriate therapy 
• Ensure completion of contact investigations 
• Evaluate program effectiveness 
• Assess trends and characteristics of TB morbidity 
 
II. TB Surveillance. For purposes of surveillance, a case of TB is defined on the basis of 
laboratory or clinical evidence of active disease due to M. tuberculosis complex.* 
________________________________ 
* Because most laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis from very 
closely related species, these laboratories report culture results as being positive or negative for “Mycobacterium 
tuberculosis complex.” Although in almost all cases of human disease, isolates in the M. tuberculosis complex are, 
in fact, M. tuberculosis, other species are possible. For example, one study in San Diego found that 6% of human 
tuberculosis was caused by Mycobacterium bovis; cultures from these cases would be reported by most laboratories 
as being positive for M. tuberculosis complex. Other species in the Mycobacterium tuberculosis complex include M. 
africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M. microti, M. canetii, M. caprae, and 
M. pinnipedii are newly described species, their inclusion in M. tuberculosis complex should not impact public 
health laboratories or programs, because only a few laboratories identify to the species level. These seven species 
are almost identical in DNA homology studies. In terms of their ability to cause clinical disease or be transmissible 
from person to person, M. bovis, M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii behave like M. 
tuberculosis; therefore, disease caused by any of the organisms should be reported as TB, using the Report of 
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Verified Case of Tuberculosis (RVCT). The only exception is the BCG strain of M. bovis, which may be isolated 
from persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused 
by the BCG strain of M. bovis should not be reported as TB. 
 
a. Laboratory Case Definition 
 
• Isolation of M. tuberculosis complex from a clinical specimen.  The use of rapid 
identification techniques for M. tuberculosis performed on a culture from a clinical 
specimen, such as DNA probes and high-pressure liquid chromatography (HPLC), is 




• Demonstration of M. tuberculosis from a clinical specimen by nucleic acid 
amplification (NAA) test. NAA tests must be accompanied by cultures of 
mycobacterial species. However, for surveillance purposes, CDC will accept results 
obtained from NAA tests approved by the Food and Drug Administration (FDA) and 
used according to the approved product labeling on the package insert, or a test 
produced and validated in accordance with applicable FDA and Clinical Laboratory 
Improvement Amendments (CLIA) regulations.      
OR    
 
• Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has 
not been or cannot be obtained or is falsely negative or contaminated; historically this 
criterion has been most commonly used to diagnose TB in the postmortem setting. 
  
 
b.   Clinical Case Definition. In the absence of laboratory confirmation of M. tuberculosis 
complex after a diagnostic process has been completed, persons must have all of the 
following criteria for clinical TB: 
 
• Evidence of TB infection based on a positive tuberculin skin test result or positive 
interferon gamma release assay for M. tuberculosis  
 
AND 
• One of the following: 
(1) Signs and symptoms compatible with current TB disease, such as an 
abnormal chest radiograph or abnormal chest computerized tomography scan or 
other chest imaging study,  
                                              OR 





• Current treatment with two or more anti-TB medications  
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NOTE:  The software for TB surveillance developed by CDC includes a calculated variable 
called “Vercrit,” for which one of the values is “Provider Diagnosis.”  “Provider Diagnosis” is 
selected when the user chooses to override a “Suspect” default value in the case verification 
screen as “Verified by Provider Diagnosis.”  Thus, “Provider Diagnosis” is not a component of 
the case definition for TB in the current “Tuberculosis Case Definition for Public Health 
Surveillance” (Appendix A).  CDC’s national morbidity reports have traditionally included all 
TB cases that are considered verified by the reporting areas, without a requirement that cases 
meet the published case definition. 
 
III.  Counting TB Cases. Cases that meet the current CDC surveillance case 
definition for verified TB are counted by 52 reporting areas with count authority 
(50 states, District of Columbia, and New York City) to determine annual 
incidence for the United States.  The remaining 8 reporting areas (American 
Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern 
Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Islands) report 
cases to CDC but are not included in the annual incidence for the United States. 
The laboratory and clinical case definitions are the two diagnostic categories used 
in the CDC “Tuberculosis Case Definition for Public Health Surveillance.” 
 
Most verified TB cases are accepted for counting based on laboratory 
confirmation of M. tuberculosis complex from a clinical specimen. 
 
A person may have more than one discrete (separate and distinct) episode of 
TB.  If disease recurs in a person within any 12-consecutive-month period after 
the patient completed therapy, count only one episode as a case. However, if TB 
disease recurs in a person, and if more than 12 months have elapsed since the 
person completed TB therapy or was lost to supervision, the TB case is 
considered a separate episode and should be counted as a new case.   
 
Mycobacterial diseases other than those caused by M. tuberculosis complex 
should not be counted in TB morbidity statistics unless there is concurrent TB.  
 
a. Verified TB Cases 
 
COUNT 
Count only verified TB cases that meet the laboratory or clinical case 
definitions (see Section II).  The diagnosis of TB must be verified by the TB 
control officer or designee.  The current CDC surveillance case definition for 
TB describes and defines the criteria to be used in the case definition for TB 
disease.  
 
DO NOT COUNT 
If diagnostic procedures have not been completed, do not count; wait for 
confirmation of disease.  Do not count as a case the patient for which two or 
more anti-TB medications have been prescribed for preventive therapy for 




b. Nontuberculous Mycobacterial Diseases (NTM) 
 
COUNT 
An episode of TB disease diagnosed concurrently with another nontuberculous 
mycobacterial disease should be counted as a TB case. 
 
DO NOT COUNT 
Disease attributed to or caused by nontuberculous mycobacteria alone should 
not be counted as a TB case. 
 
c. TB Cases Reported at Death 
 
COUNT 
TB cases first reported to the health department at the time of a person’s death 
are counted as incident cases, provided the person had current disease at the 
time of death. The TB control officer should verify the diagnosis of TB. 
 
DO NOT COUNT 
Do not count as a case of TB if there is no evidence of current disease at the 
time of death or at autopsy. 
 





Immigrants and refugees who are examined after arriving in the United States 
and diagnosed with clinically active TB requiring anti-TB medications should 
be reported and counted by the locality of their current residence at the time of 
diagnosis regardless of citizenship status. 
 
Border crossers* who are diagnosed with TB and plan to receive anti-TB 
therapy from a locality in the United States for 90 days or more should be 
reported and counted by the locality where they receive anti-TB therapy. 
 
Foreign visitors (e.g., students, commercial representatives, and diplomatic 
personnel) who are diagnosed with TB, are receiving anti-TB therapy, and have 
been, or plan to remain in, the United States for 90 days or more should be 
reported and counted by the locality of current residence. 
 
*Border crosser — defined, by the U.S. Citizenship and Immigration Services 
(USCIS)2 as “an alien resident of the United States reentering the country after 
an absence of less than six months in Canada or Mexico, or a nonresident alien 
entering the United States across the Canadian border for stays of no more than 
six months, or across the Mexican border for stays of no more than 72 hours.” 




DO NOT COUNT 
Any person who was diagnosed and started on anti-TB drugs in another country 
should not be counted as a new case but should be reported as a verified 
noncountable TB case.   
 
Border crossers* and foreign visitors who are diagnosed with TB and receive 
anti-TB therapy from a locality in the United States for less than 90 days but 
plan to return to their native country to continue therapy should not be reported 
or counted by the locality where they receive anti-TB therapy. 
 
e. Out-of-State or Out-of-Area Residents  
 
COUNT  
A person’s TB case should be counted by the locality in which he or she resides 
at the time of diagnosis.  TB in a person who has no address should be counted 
by the locality that diagnosed and is treating the TB.  The TB control officer 
should notify the appropriate out-of-state or out-of-area TB control officer of 
the person’s home locality to (1) determine whether the case has already been 
counted to avoid “double counting,” and (2) agree on which TB control office 
should count the case if it has not yet been counted.  
 
DO NOT COUNT  
Do not count a case in a newly diagnosed TB patient who is an out-of-area 
resident and whose TB has already been counted by the out-of-area TB control 
office.   
 
f. Migrants and Other Transients  
 
COUNT 
Persons without any fixed U.S. residence are considered to be the public health 
responsibility of their present locality and their TB case should be reported and 
counted where diagnosed. 
 
DO NOT COUNT 
Cases in transient TB patients should not be counted when there is evidence that 
they have already been counted by another locality.   
 
g. Federal Facilities (e.g., Military and Veterans Administration Facilities)   
 
COUNT 
Cases in military personnel, dependents, or veterans should be reported and 
counted by the locality where the persons are residing in the United States at the 
time of diagnosis and initiation of treatment. 
 
However, if military personnel or dependents are discovered to have TB at a 
military base outside the United States but are referred elsewhere for treatment 
(e.g., a military base located within the United States), the TB case should be 
reported and counted where treated and not where the diagnosis was made. 
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DO NOT COUNT 
Do not count if the case was already counted by another locality in the United 
States.  
 
h. Indian Health Service 
 
COUNT 
TB should be reported to the local health authority (e.g., state or county) and 
counted where diagnosed and treatment initiated.  However, for a specific group 
such as the Navajo Nation, which is geographically located in multiple states, 
health departments should discuss each case and determine which locality 
should count the case. 
 
DO NOT COUNT 
Do not count if the case was already counted by another locality.  
 
i. Correctional Facilities (e.g., Local, State, Federal, and Military) 
 
COUNT 
Persons who reside in local, state, federal, or military correctional facilities may 
frequently be transferred or relocated within and/or between various 
correctional facilities. TB in these persons should be reported to the local health 
authority and counted by the locality where the diagnosis was made and 
treatment plans were initiated. 
 
DO NOT COUNT 
Do not count correctional facility residents’ TB cases that were counted 
elsewhere by another locality or correctional facility, even if treatment 
continues at another locale or correctional facility.  
 
j. Peace Corps, Missionaries, and Other Citizens Residing Outside the United 
States 
 
DO NOT COUNT 
TB in persons diagnosed outside the United States should not be counted.  TB in 
these persons should be counted by the country in which they are residing, 
regardless of their plans to return to the United States for further work-up or 
treatment. 
 
IV. Suggested Administrative Practices 
 
To promote uniformity in TB case counting, the following administrative 
procedures are recommended: 
 
(a) All TB cases verified by the 52 reporting areas with count authority (50 states, 
District of Columbia, and New York City) during the calendar year (by 
December 31) will be included in the annual U.S. incidence count for that 
year. All tuberculosis cases verified during the calendar year by a reporting 
area with count authority from one of the remaining 8 reporting areas 
(American Samoa, Federated States of Micronesia, Guam, Marshall Islands, 
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Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin 
Islands) are also counted but are not included in the annual incidence for the 
United States. Cases for which bacteriologic results are pending or for which 
confirmation of disease is questionable for any other reason should not be 
counted until their status is clearly determined; they should be counted at the 
time they meet the criteria for counting. This means that a case reported in one 
calendar year could be included in the morbidity count for the following year. 
The reporting area with count authority should ensure that there is agreement 
between final local and state TB figures reported to CDC. Currently, some 
reporting areas may not use this suggested protocol. Some of these areas may 
wait until the beginning of the following year when they have received and 
processed all of the TB cases for inclusion in the annual case count for the 
previous year.  If reporting areas decide to revise their protocols, they should 
be aware that their TB trends may change. 
 
(b) TB is occasionally reported to health departments over the telephone, by letter 
or fax, or on forms other than the Report of Verified Case of Tuberculosis 
(RVCT). Such information should be accepted as an official morbidity report 
if sufficient details are provided; otherwise, the notification should be used as 
an indicator of a possible TB case (suspect) which should be investigated 
promptly for confirmation. 
 
V. TB Surveillance Definitions 
 
Case - an episode of TB disease in a person meeting the laboratory or clinical 
criteria for TB as defined in the document “Tuberculosis Case Definition for 
Public Health Surveillance” (see Section II for criteria). 
 
Suspect - a person for whom there is a high index of suspicion for active TB 
(e.g., a known contact to an active TB case or a person with signs or symptoms 
consistent with TB) who is currently under evaluation for TB disease. 
 
Verification of a TB case - the process whereby a TB case, after the diagnostic 
evaluation is complete, is reviewed at the local level (e.g., state or county) by a 
TB control official who is familiar with TB surveillance definitions; if all the 
criteria for a TB case are met, the TB case is then verified and eligible for 
counting.  
 
Counting of a TB case - the process whereby a reporting area with count 
authority evaluates verified TB cases against count criteria (e.g., assesses for 
case duplication). These cases are then counted for morbidity in that locality 
(e.g., state or county) and reported to CDC for national morbidity counting. 
Noncountable, verified cases may also be sent to CDC. 
 
Mycobacterium tuberculosis complex (M. tuberculosis complex) - Because 
most laboratories use tests that do not routinely distinguish Mycobacterium 
tuberculosis from very closely related species, these laboratories report culture 
results as being positive or negative for “Mycobacterium tuberculosis complex.” 
Although in almost all cases of human disease, isolates in the M. tuberculosis 
complex are, in fact, M. tuberculosis, other species are possible. For example, 
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one study in San Diego found that 6% of human tuberculosis was caused by 
Mycobacterium bovis; cultures from these cases would be reported by most 
laboratories as being positive for M. tuberculosis complex. Other species in the 
Mycobacterium tuberculosis complex include M. africanum, M. microti, M. 
canetii, M. caprae, and M. pinnipedii. Although M. microti, M. canetii, M. 
caprae, and M. pinnipedii are newly described species, their inclusion in M. 
tuberculosis complex should not impact public health laboratories or programs 
because only a few laboratories identify to the species level. These seven 
species are almost identical in DNA homology studies. In terms of their ability 
to cause clinical disease or be transmissible from person to person, M. bovis, M. 
africanum, M. microti, M. canetti, M. caprae, and M. pinnipedii behave like M. 
tuberculosis; therefore, disease caused by any of the organisms should be 
reported as TB, using the Report of Verified Case of Tuberculosis (RVCT). The 
only exception is the BCG strain of M. bovis, which may be isolated from 
persons who have received the vaccine for protection against TB or as cancer 
immunotherapy; disease caused by the BCG strain of M. bovis should not be 
reported as TB. 
  
Nontuberculous mycobacteria (NTM) - mycobacteria other than 
Mycobacterium tuberculosis complex that can cause human infection or disease.  
Common nontuberculous mycobacteria include M. avium complex or MAC (M. 
avium, M. intracellulare), M. kansasii, M. marinum, M. scrofulaceum, M. 
chelonae, M. fortuitum, and M. simiae.  Other terms have been used to represent 
NTM, including MOTT (mycobacteria other than TB) and “atypical” 
mycobacteria. 
 
Reporting area - areas responsible for counting and reporting verified TB cases 
to CDC.  Currently there are 60 reporting areas: the 50 states, District of 
Columbia, New York City, American Samoa, Federated States of Micronesia, 
Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of 
Palau, and U.S. Virgin Islands.  The annual incidence of tuberculosis for the 
United States is based on 52 reporting areas (the 50 states, District of Columbia, 
and New York City). 
 
Alien - defined by the U.S. Citizenship and Immigration Services (USCIS)2 as 
“any person not a citizen or national of the United States.” 
 
Border crosser - defined, by the U.S. Citizenship and Immigration Services 
(USCIS)2 as “an alien resident of the United States reentering the country after 
an absence of less than six months in Canada or Mexico, or a nonresident alien 
entering the United States across the Canadian border for stays of no more than 
six months, or across the Mexican border for stays of no more than 72 hours.”  
Border crossers may go back and forth across the border many times in a short 
period. 
 
Class A TB with waiver3  
 
All applicants who have tuberculosis disease and have been granted a waiver.  
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Class B1 TB, Pulmonary3  
  
 No treatment  
• Applicants who have medical history, physical exam, HIV, or CXR 
findings suggestive of pulmonary TB but have negative AFB sputum 
smears and cultures and are not diagnosed with TB or can wait to have 
TB treatment started after immigration.  
 
Completed treatment  
• Applicants who were diagnosed with pulmonary TB and successfully 
completed directly observed therapy prior to immigration. The cover 
sheet should indicate if the initial sputum smears and cultures were 
positive and if drug susceptibility testing results are available.  
 
Class B1 TB, Extrapulmonary3  
 
Applicants with evidence of extrapulmonary TB. Document the anatomic site of 
infection.  
 
Class B2 TB, Latent TB Infection (LTBI) Evaluation3  
 
Applicants who have a tuberculin skin test ≥10 mm but otherwise have a 
negative evaluation for TB. The size of the TST reaction, the applicant’s status 
with respect to LTBI treatment, and the medication(s) used should be 
documented. For applicants who had more than one TST, whether the applicant 
converted the TST should be documented (i.e., initial TST <10 mm but 
subsequent TST ≥10 mm).  
 
Class B3 TB, Contact Evaluation3  
  
Applicants who are a recent contact of a known tuberculosis case. The size of 
the applicant’s TST reaction should be documented. Information about the 
source case, name, alien number, relationship to contact, and type of 
tuberculosis should also be documented. 
 
Immigrant - defined by the USCIS2  as “an alien admitted to the United States 
as a lawful permanent resident.  Immigrants are those persons lawfully accorded 
the privilege of residing permanently in the United States.  They may be issued 
immigrant visas by the Department of State overseas or adjusted to permanent 
resident status by the USCIS of the United States.” 
 
Permanent Resident Alien - see Immigrant.  
 
 147
Waivers3 - A provision allows applicants undergoing pulmonary or laryngeal 
tuberculosis treatment to petition for a Class A TB with waiver. Waivers should 
be pursued for any immigrant or refugee who has a complicated clinical course 
and would benefit from receiving treatment of their tuberculosis in the United 
States. Applicants diagnosed with tuberculosis disease who are both smear- and 
culture-negative and will be traveling to the United States prior to start of 




1. Recommendations for Counting Reported TB Cases. Atlanta: CDC, July 
1997.  
2. U.S. Department of Homeland Security, U.S. Citizenship and Immigration 
Services; http://uscis.gov. Accessed March 2009. 
3. 2007 Technical Instructions for Tuberculosis Screening and Treatment for 
Panel Physicians. Atlanta: CDC, Division of Global Migration and 
Quarantine. http://www.cdc.gov/ncidod/dq/panel_2007.htm. Accessed 






Anatomic Code Anatomic Code 
Dermal System 
00  * Skin and skin appendages 
01  * Subcutaneous Tissue 
02  * Breast 
03 Milk 
Cardiovascular System 
30  * Pericardium 
31  * Heart 
32  * Cardiac valve 
33 Pericardial fluid 
34  * Blood vessel 
Hematopoietic System 
04  * Bone marrow 
05  * Spleen 
06  * Blood 
Gastrointestinal System 
35  * Mouth 
36  * Lip 
37  * Tongue 
38  * Tooth, gum, and supporting structures 
of the tooth 
39  * Salivary gland 
40  * Liver 
41  * Gallbladder 
42  * Extrahepatic bile duct 
43  * Pancreas 
44 Saliva 
45 Bile and pancreatic fluid 
46  * Pharynx, oropharynx, and hypopharynx 
47  * Tonsils and adenoids 
48  * Esophagus 
49  * Stomach 
50  * Small intestine - duodenum 
51  * Small intestine - jejunum & ileum 
52  * Appendix 
53  * Colon 
54  * Rectum 
55  * Anus 
56 Gastric aspirate 
57 Gastrointestinal contents (feces) 
58 Omentum and peritoneum 
59 Peritoneal fluid 
Lymphatic System 
07    Lymph node 
Musculoskeletal System 
08 Bone, NOS (Not Otherwise Specified) 
09 Skeletal system (Bones of head, ribcage,   
and vertebral column) 
10 Skeletal system (Bones of shoulder,  
girdle, pelvis, and extremities) 
11 Soft tissue, NOS (Not Otherwise    
Specified) 
12 Soft tissue (Muscles of head, neck, 
mouth, and upper extremity) 
13 Soft tissue (Muscles of trunk, perineum,  
and lower extremity) 
14 Tendon and tendon sheath 
15 Ligament and fascia 
16 Joints (Synovial tissue) 
17 Synovial fluid 
Respiratory System 
18  * Nose 
19  * Accessory Sinus 
20  * Nasopharynx 
21  * Epiglottis 





27 Upper respiratory fluids or tracheal fluids 
28 Bronchial fluid 
29 Pleural fluid 






61 Renal pelvis 
62 Ureter 
63 Urinary bladder 
64 Urethra 
65 Penis 
66 Prostate and seminal vesicle 
67 Testis  
68 Epididymis, vas deferens, spermatic 
cord, and scrotum 
69 Urine 
70 Male genital fluids 







77 Fallopian tube, broad ligament, 
parametrium, and parovarian region 
78 Ovary 
79 Female genital fluids 
Fetal Structures 
80  * Placenta, umbilical cord, and 
implantation site 
81  * Fetus and embryo 
Endocrine System 
82  * Pituitary gland 
83  * Adrenal gland 
84  * Thyroid or parathyroid gland(s) 
85  * Thymus 
Neurological System 
86 CSF (Cerebral spinal fluid) 
87 Meninges, dural sinus, choroid plexus 
88  * Brain 
89  * Spinal cord 
90  * Cranial, spinal, and peripheral nerve 
91  * Eye and ear appendages 
92  * Ear and mastoid cells 
Other 
93 Pus 
94  * Other 
95 Multiple Sites 
99 Unknown 
 
*  Only codes marked with an asterisk (*) should be used when a Site of Disease (item 16) is Other. 
Appendix D 
Reporting Area Codes 
 
 
Reporting Area Codes 
Name Alpha Code  Name Alpha Code 
Alabama AL 01  Nebraska NE 31 
Alaska AK 02  Nevada NV 32 
Arizona AZ 04  New Hampshire NH 33 
Arkansas AR 05  New Jersey NJ 34 
California CA 06  New Mexico NM 35 
Colorado CO 08  New York NY 36 
Connecticut CT 09  New York City NO 975772 
Delaware DE 10  North Carolina NC 37 
Florida FL 12  North Dakota ND 38 
Georgia GA 13  Ohio OH 39 
Hawaii HI 15  Oklahoma OK 40 
Idaho ID 16  Oregon OR 41 
Illinois IL 17  Pennsylvania PA 42 
Indiana IN 18  Rhode Island RI 44 
Iowa IA 19  South Carolina SC 45 
Kansas KS 20  South Dakota SD 46 
Kentucky KY 21  Tennessee TN 47 
Louisiana LA 22  Texas TX 48 
Maine ME 23  Utah UT 49 
Maryland MD 24  Vermont VT 50 
Massachusetts MA 25  Virginia VA 51 
Michigan MI 26  Washington WA 53 
Minnesota MN 27  Washington D.C. DC 11 
Mississippi MS 28  West Virginia WV 54 
Missouri MO 29  Wisconsin WI 55 
Montana MT 30  Wyoming WY 56 
 
U.S. Island Reporting Area Codes 
For information on citizenship and “U.S.-born” for the U.S. Island Areas see Country of Birth (item 12)  
 Name Alpha 
 
Code  Name Alpha 
 
Code 
American Samoa AQ 60  Palau PS 70 
Federated States of 
Micronesia 
FM 64  Puerto Rico PR 72 






























Bahamas, The BHS 
Bahrain BHR 
Baker Island FQ 
Bangladesh BGD 
Barbados BRB 








Bosnia and Herzegovina BIH 
Botswana BWA 
Bouvet Island BVT 
British Indian Ocean Territory IOT 
Brazil BRA 
British Virgin Islands VGB 
Brunei BRN 
Bulgaria BGR 






Cape Verde CPV 
Cayman Islands CYM 
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Country Alpha Code 




Christmas Island CXR 
Clipperton Island IP 




Cook Islands COK 
Coral Sea Islands CR 









Dominican Republic DOM 
Ecuador ECU 
Egypt EGY 
El Salvador SLV 




Europa Island EU 
Falkland Islands (Malvinas) FLK 
Faroe Islands FRO 
Federated States of Micronesia FSM 
Fiji FJI 
Finland FIN 
French Southern and Antarctic Lands ATF 
France FRA 
French Guiana GUF 
French Polynesia PYF 
Gabon GAB 
Gambia, The GMB 



















Heard Island and McDonald Islands HMD 
Honduras HND 
Hong Kong HKG 











Ivory Coast CIV 
Jamaica JAM 
Jan Mayen JN 
Japan JPN 
Jarvis Island DQ 
Jersey JEY 
Johnston Atoll JQ 
Jordan JOR 
Juan De Nova Island JU 
Kazakhstan KAZ 
Kenya KEN 
Kingman Reef KQ 
Kiribati KIR 
Korea, Republic of KOR 






















Man, Isle of IMN 

















Navassa Island BQ 
Nepal NPL 
Netherlands NLD 
Netherlands Antilles ANT 
New Caledonia NCL 





Norfolk Island NFK 
Northern Mariana Islands MNP 
Norway NOR 




Palmyra Atoll LQ 
Panama PAN 
Papua New Guinea PNG 




Pitcairn Islands PCN 
Poland POL 
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Country Alpha Code 
Portugal PRT 
Portuguese Timor TPTL 






South Georgia/South Sandwich Islands SGS 
San Marino SMR 
Sao Tome and Principe STP 




Sierra Leone SLE 
Singapore SGP 
Slovak Republic SVK 
Slovenia SVN 
Solomon Islands SLB 
Somalia SOM 
South Africa ZAF 
Soviet Union SUHH 
Spain ESP 
Spratly Islands PG 
Sri Lanka LKA 
St Lucia LCA 
St. Helena SHN 
St. Kitts and Nevis KNA 
St. Pierre and Miquelon SPM 















Tonga, Kingdom of TON 
Trinidad and Tobago TTO 




Country Alpha Code 
Turkmenistan TKM 
Turks and Caicos Islands TCA 
Tuvalu TUV 
U.S. Minor Outlying Islands UMI 
Uganda UGA 
Ukraine UKR 
United Arab Emirates ARE 
United Kingdom GBR 
United States USA 
Uruguay URY 
U.S. Miscellaneous Pacific Islands PUUM 
Uzbekistan UZB 
Vanuatu (New Hebrides) VUT 
Vatican City VAT 
Venezuela VEN 
Vietnam VNM 
Virgin Islands VIR 
Wake Island WKUM 
Wallis and Futuna WLF 
West Bank WE 
Western Sahara ESH 














Acid-fast bacilli (AFB) Microorganisms that when stained, retain color even after they have been 
washed in an acid solution; may be detected under a microscope in a stained 
smear. 
 
Active case finding Looking for undiagnosed cases by screening a population. 
 
Active TB disease An illness, caused by bacteria called Mycobacterium tuberculosis, in which 
tuberculosis (TB) bacteria are multiplying and attacking parts of the body, 
most commonly the lungs. A person with active TB disease is capable of 
spreading the disease to others if the TB bacteria are active in the lungs or 
throat. The symptoms of active TB disease include weakness, weight loss, 
fever, no appetite, chills, and sweating at night. Other symptoms may 
include a bad cough, pain in the chest, and coughing up blood.  
 
Adherence to treatment Following the recommended course of treatment by taking all the 
prescribed medications for the entire length of time necessary. 
 
Adverse effect Negative side effect resulting from the use of a drug (for example, hepatitis, 
nausea, headache). 
 
Bronchoscopy A procedure used to obtain pulmonary secretions or lung tissue with an 
instrument called a bronchoscope. 
 
Case management A system in which a specific health department employee is assigned 
primary responsibility for the patient, systematic regular review of patient 
progress is conducted, and plans are made to address any barriers to 
adherence. 
 
Case rate The number of cases that occur during a certain time period, divided by the 
size of the population during that time period; the case rate is often 
expressed in terms of a population size of 100,000 persons. 
 
Case reporting Informing the state or local health department when a new case (an 
occurrence) of TB disease has been diagnosed or is suspected. 
 
Cavity A hollow space within the lung, visible on a chest x-ray or CT scan.  
 
Clinical evaluation An evaluation done to find out whether a patient has symptoms of TB 
disease or is responding to treatment; also done to check for adverse 
reaction to TB medications. 
 
Clinician A physician, physician’s assistant, or nurse. 
 
Congregate setting A setting in which a group of usually unrelated persons reside in close 
physical proximity. These settings may include hospitals, long-term care 
facilities, assisted living facilities, correctional facilities, or homeless 





Contact investigation A procedure for interviewing a person who has TB disease to determine 
who may have been exposed to TB. People who have been exposed to TB 
are tested for latent TB infection (LTBI) and TB disease. 
 
Contacts People exposed to someone with infectious TB disease, generally including 
family members, roommates or housemates, close friends, coworkers, 
classmates, and others. 
 
Country of birth The country where a person was born. 
 
Culture To grow organisms on media (substances containing nutrients) so that they 
or the product of this process can be identified. 
 
Daily regimen A treatment schedule in which the patient takes a dose of each prescribed 
medication every day. 
 
Diabetes mellitus A disease in which the body's ability to use sugar is altered. 
 
Diagnostic evaluation An evaluation used to diagnose TB disease; includes a medical history, a 
chest x-ray, the collection of specimens for bacteriologic examination, and 
possibly a tuberculin skin test or an interferon-gamma release assay such as 




A designated person watches the TB patient swallow each dose of the 
prescribed drugs. 
 
Drug susceptibility test A laboratory method for finding drug resistance in a microorganism.  
 
Drug-resistant TB TB caused by organisms that are able to grow in the presence of a particular 
drug; TB that is resistant to at least one first-line antituberculosis drug. 
 
End-stage renal disease 
(ESRD) 
A condition when chronic kidney failure has progressed to the point where 
kidney function is less than 10% of normal; requires dialysis or 
transplantation; also known as stage 5 chronic kidney disease. The most 
common cause of ESRD in the United States is diabetes. 
 
Ethambutol (EMB) A drug used to treat TB disease; may cause vision problems. Ethambutol 
should be used cautiously in children who are too young to be monitored for 
changes in their vision. 
 
Extrapulmonary TB TB disease that occurs in places other than the lungs, such as the lymph 
nodes, the pleura, the brain, the kidneys, or the bones; most types of 
extrapulmonary TB are not infectious. 
 
First-line TB drugs The initial drugs used for treating TB disease.  Include isoniazid (INH), 
rifampin (RIF), pyrazinamide (PZA), and either ethambutol (EMB). or 
streptomycin (SM). 
 
Foreign-born persons People born outside of the United States. 
 






Therapy that suppresses or weakens the immune system. 
Interferon-gamma  
(IFN-γ) 
Protein that is normally produced by the body in response to infection.  
 
Interferon-gamma 
release assay (IGRA) 
A type of blood test that measures a person’s immune reactivity to M. 
tuberculosis by measuring release of IFN-γ. In the U.S., QuantiFERON®-
TB Gold, QuantiFERON®-TB Gold In-Tube, and T-SPOT®.TB are 
currently available IGRAs. 
 
Isolate A sample from a specimen that was identified as a certain organism such as 
M. tuberculosis complex. 
 
Isoniazid (INH) A drug that is used for treating LTBI and one of the drugs used to treat TB 
disease; although relatively safe, it may cause hepatitis and other severe 
adverse reaction in some patients. 
 
Latent TB infection 
(LTBI) 
Refers to the condition when a person is infected with tubercle bacilli, but 
TB disease has not developed. Persons with LTBI do not have TB disease 
symptoms and they cannot spread TB germs to others. Persons with LTBI 
usually have a positive result to the Mantoux tuberculin skin test or an 
interferon-gamma release assay. 
 
LTBI treatment Medication that is given to people who have latent TB infection to prevent 
them from developing TB disease. 
 
Mantoux tuberculin skin 
test (TST) 
A method of testing for TB infection; a needle and syringe are used to inject 
0.1 ml of 5 tuberculin units of liquid tuberculin between the layers of the 
skin (intradermally), usually on the forearm; the reaction to this test, a 
palpable swollen area (induration), is measured 48 to 72 hours after the 
injection and is interpreted as positive or negative depending on the size of 
the reaction and the patient’s risk factors for TB. 
 
Miliary TB Miliary TB is a serious type of tuberculosis infection. It is a histological or 
radiologic finding, rather than a site of disease. It appears on radiograph as a 
great number of small, well-defined nodules that look like millet seeds 
scattered throughout the lungs, hence the name “miliary.”  
 
Multidrug-resistant TB 
(MDR TB)  
Resistant to at least the drugs isoniazid and rifampin; MDR TB is more 




One of the organisms causing TB in humans, and sometimes called the 




A group of closely related mycobacteria that can cause active TB (e.g., M. 
tuberculosis, M. bovis, and M. africanum). Most TB in the United States is 




A technique that amplifies (copies) DNA or RNA segments, in order to 




Pulmonary TB TB disease that occurs in the lungs, typically causing a cough and an 
abnormal chest x-ray. Pulmonary TB is usually infectious if untreated. Most 
TB cases reported in the United States are pulmonary TB. 
 
Pyridoxine Another name for vitamin B6; it is given to prevent peripheral neuropathy; 
should always be given to pregnant and breastfeeding women on isoniazid. 
 
QuantiFERON®-TB 
Gold test (QFT-G) 
A blood test used for diagnosing infection with M. tuberculosis. The QFT-G 
measures a patient’s immune reactivity to M. tuberculosis by measuring the 
response to TB proteins when they are mixed with a small amount of blood 
(see IGRAs). 
 
Recurrence A patient who has either a  
• Negative culture result while receiving anti-TB therapy, but at some 
point after therapy is completed, either the culture result becomes 
positive for M. tuberculosis or the patient has clinical or radiologic 
deterioration that is consistent with TB disease. 
or  
• Negative smear and culture result (e.g., clinical case) at diagnosis 
and while receiving anti-TB therapy, but at some point after therapy 
is completed, either the patient has a culture result that is positive for 
M. tuberculosis or has clinical or radiologic deterioration that is 
consistent with TB disease. 
 
Rifabutin A drug used to treat TB disease; used as a substitute for rifampin (RIF) in 
the treatment of all forms of TB. 
 
Rifampin A drug used to treat TB disease; also used for LTBI treatment. Rifampin 
has several possible side effects (for example, hepatitis, turning body fluids 
orange, and drug interactions). 
 
Rifapentine A drug used to treat TB disease; used once weekly with isoniazid during the 
continuation phase with selected HIV-negative patients. 
 
Second-line TB drugs  Drugs used to treat TB that is resistant to first-line TB drugs (for example, 
capreomycin, kanamycin, ethionamide, cycloserine, ciprofloxacin, 
amikacin). 
 
Smear A specimen that has been smeared onto a glass slide, stained, washed in an 
acid solution, and then placed under the microscope for examination; used 
to detect acid-fast bacilli in a specimen. 
 
Specimen A sample collected from a person for testing. 
 
Sputum Phlegm from deep in the lungs, collected in a sterile container for 
processing and examination. 
 




Suspect A person for whom there is a high index of suspicion for active TB (e.g., a 
known contact to an active TB case or to a person with signs or symptoms 
consistent with TB) who is currently under evaluation for TB disease. 
 
XDR TB The occurrence of TB in persons whose M. tuberculosis isolates are 
resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and 









































For more information, contact 
 
 
U.S. Department of Health and Human Services 
Centers for Disease Control and Prevention 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention 
Division of Tuberculosis Elimination 
1600 Clifton Road N.E. 
MS E-10 
Atlanta, GA 30333 
 
Phone (404) 639-8120 
Fax: (404) 639-8959
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